{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T10:01:55Z","timestamp":1789639315388,"version":"4.0.0"},"reference-count":280,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1038\/s41401-026-01892-9","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T06:35:55Z","timestamp":1785825355000},"page":"2791-2819","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Beyond conventional therapies: the evolution of targeted agents and immunotherapies in triple-negative breast cancer"],"prefix":"10.1038","volume":"47","author":[{"given":"Hui-fang","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-mei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-yan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai-zhuo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,4]]},"reference":[{"key":"1892_CR1","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41571-021-00565-2","volume":"19","author":"G Bianchini","year":"2022","unstructured":"Bianchini G, De Angelis C, Licata L, Gianni L. Treatment landscape of triple-negative breast cancer - expanded options, evolving needs. Nat Rev Clin Oncol. 2022;19:91\u2013113.","journal-title":"Nat Rev Clin Oncol"},{"key":"1892_CR2","doi-asserted-by":"publisher","first-page":"e071674","DOI":"10.1136\/bmj-2022-071674","volume":"381","author":"RA Leon-Ferre","year":"2023","unstructured":"Leon-Ferre RA, Goetz MP. Advances in systemic therapies for triple negative breast cancer. BMJ. 2023;381:e071674.","journal-title":"BMJ"},{"key":"1892_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-022-00468-0","volume":"8","author":"P Zagami","year":"2022","unstructured":"Zagami P, Carey LA. Triple negative breast cancer: Pitfalls and progress. NPJ Breast Cancer. 2022;8:95.","journal-title":"NPJ Breast Cancer"},{"key":"1892_CR4","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nrclinonc.2016.66","volume":"13","author":"G Bianchini","year":"2016","unstructured":"Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2016;13:674\u201390.","journal-title":"Nat Rev Clin Oncol"},{"key":"1892_CR5","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/s41586-019-1056-z","volume":"569","author":"F Bertucci","year":"2019","unstructured":"Bertucci F, Ng CKY, Patsouris A, Droin N, Piscuoglio S, Carbuccia N, et al. Genomic characterization of metastatic breast cancers. Nature. 2019;569:560\u20134.","journal-title":"Nature"},{"key":"1892_CR6","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/nrclinonc.2010.154","volume":"7","author":"L Carey","year":"2010","unstructured":"Carey L, Winer E, Viale G, Cameron D, Gianni L. Triple-negative breast cancer: disease entity or title of convenience? Nat Rev Clin Oncol. 2010;7:683\u201392.","journal-title":"Nat Rev Clin Oncol"},{"key":"1892_CR7","doi-asserted-by":"publisher","first-page":"vi19","DOI":"10.1093\/annonc\/mds190","volume":"23","author":"F Penault-Llorca","year":"2012","unstructured":"Penault-Llorca F, Viale G. Pathological and molecular diagnosis of triple-negative breast cancer: a clinical perspective. Ann Oncol. 2012;23:vi19\u201322.","journal-title":"Ann Oncol"},{"key":"1892_CR8","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1200\/JCO.2011.38.2010","volume":"30","author":"O Metzger-Filho","year":"2012","unstructured":"Metzger-Filho O, Tutt A, de Azambuja E, Saini KS, Viale G, Loi S, et al. Dissecting the heterogeneity of triple-negative breast cancer. J Clin Oncol. 2012;30:1879\u201387.","journal-title":"J Clin Oncol"},{"key":"1892_CR9","doi-asserted-by":"publisher","first-page":"3466","DOI":"10.1158\/0008-5472.CAN-18-3014","volume":"79","author":"RL Stewart","year":"2019","unstructured":"Stewart RL, Updike KL, Factor RE, Henry NL, Boucher KM, Bernard PS, et al. A multigene assay determines risk of recurrence in patients with triple-negative breast cancer. Cancer Res. 2019;79:3466\u201378.","journal-title":"Cancer Res"},{"key":"1892_CR10","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1200\/JCO.20.03399","volume":"39","author":"LA Korde","year":"2021","unstructured":"Korde LA, Somerfield MR, Carey LA, Crews JR, Denduluri N, Hwang ES, et al. Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline. J Clin Oncol. 2021;39:1485\u2013505.","journal-title":"J Clin Oncol"},{"key":"1892_CR11","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1093\/annonc\/mdz158","volume":"30","author":"S Loibl","year":"2019","unstructured":"Loibl S, Untch M, Burchardi N, Huober J, Sinn BV, Blohmer JU, et al. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study. Ann Oncol. 2019;30:1279\u201388.","journal-title":"Ann Oncol"},{"key":"1892_CR12","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1158\/0008-5472.CAN-20-3094","volume":"81","author":"F Wang","year":"2021","unstructured":"Wang F, Zheng W, Bailey CE, Mayer IA, Pietenpol JA, Shu XO. Racial\/ethnic disparities in all-cause mortality among patients diagnosed with triple-negative breast cancer. Cancer Res. 2021;81:1163\u201370.","journal-title":"Cancer Res"},{"key":"1892_CR13","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1186\/s13046-022-02476-1","volume":"41","author":"K Asleh","year":"2022","unstructured":"Asleh K, Riaz N, Nielsen TO. Heterogeneity of triple-negative breast cancer: current advances in subtyping and treatment implications. J Exp Clin Cancer Res. 2022;41:265.","journal-title":"J Exp Clin Cancer Res"},{"key":"1892_CR14","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1038\/nrclinonc.2009.166","volume":"6","author":"B Weigelt","year":"2009","unstructured":"Weigelt B, Reis-Filho JS. Histological and molecular types of breast cancer: is there a unifying taxonomy? Nat Rev Clin Oncol. 2009;6:718\u201330.","journal-title":"Nat Rev Clin Oncol"},{"key":"1892_CR15","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1038\/s41568-024-00714-6","volume":"24","author":"MA Harris","year":"2024","unstructured":"Harris MA, Savas P, Virassamy B, O\u2019Malley MMR, Kay J, Mueller SN, et al. Towards targeting the breast cancer immune microenvironment. Nat Rev Cancer. 2024;24:554\u201377.","journal-title":"Nat Rev Cancer"},{"key":"1892_CR16","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1093\/annonc\/mdy024","volume":"29","author":"Y Bareche","year":"2018","unstructured":"Bareche Y, Venet D, Ignatiadis M, Aftimos P, Piccart M, Rothe F, et al. Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis. Ann Oncol. 2018;29:895\u2013902.","journal-title":"Ann Oncol"},{"key":"1892_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0850-9","volume":"17","author":"Y Shi","year":"2018","unstructured":"Shi Y, Jin J, Ji W, Guan X. Therapeutic landscape in mutational triple-negative breast cancer. Mol Cancer. 2018;17:99.","journal-title":"Mol Cancer"},{"key":"1892_CR18","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ctrv.2018.05.014","volume":"68","author":"X Wang","year":"2018","unstructured":"Wang X, Shi Y, Huang D, Guan X. Emerging therapeutic modalities of PARP inhibitors in breast cancer. Cancer Treat Rev. 2018;68:62\u20138.","journal-title":"Cancer Treat Rev"},{"key":"1892_CR19","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1038\/s41591-019-0582-4","volume":"25","author":"J Staaf","year":"2019","unstructured":"Staaf J, Glodzik D, Bosch A, Vallon-Christersson J, Reutersw\u00e4rd C, H\u00e4kkinen J, et al. Whole-genome sequencing of triple-negative breast cancers in a population-based clinical study. Nat Med. 2019;25:1526\u201333.","journal-title":"Nat Med"},{"key":"1892_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17537-2","volume":"11","author":"D Glodzik","year":"2020","unstructured":"Glodzik D, Bosch A, Hartman J, Aine M, Vallon-Christersson J, Reutersw\u00e4rd C, et al. Comprehensive molecular comparison of BRCA1 hypermethylated and BRCA1-mutated triple-negative breast cancers. Nat Commun. 2020;11:3747.","journal-title":"Nat Commun"},{"key":"1892_CR21","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1158\/1078-0432.CCR-14-0432","volume":"21","author":"MD Burstein","year":"2015","unstructured":"Burstein MD, Tsimelzon A, Poage GM, Covington KR, Contreras A, Fuqua SAW, et al. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin Cancer Res. 2015;21:1688\u201398.","journal-title":"Clin Cancer Res"},{"key":"1892_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2025.103889","volume":"80","author":"X Ren","year":"2025","unstructured":"Ren X, Zhou T, Song Y, Wu H, Chou J, Miller LD, et al. Intrinsic subtype and immunity score in identification of triple-negative breast cancer at low risk. Breast. 2025;80:103889.","journal-title":"Breast"},{"key":"1892_CR23","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1080\/13543784.2022.2049232","volume":"31","author":"E Agostinetto","year":"2022","unstructured":"Agostinetto E, Losurdo A, Nader-Marta G, Santoro A, Punie K, Barroso R, et al. Progress and pitfalls in the use of immunotherapy for patients with triple-negative breast cancer. Expert Opin Investig Drugs. 2022;31:567\u201391.","journal-title":"Expert Opin Investig Drugs"},{"key":"1892_CR24","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.cell.2023.11.037","volume":"187","author":"J Pozniak","year":"2024","unstructured":"Pozniak J, Pedri D, Landeloos E, Van Herck Y, Antoranz A, Vanwynsberghe L, et al. A TCF4-dependent gene regulatory network confers resistance to immunotherapy in melanoma. Cell. 2024;187:166\u201383.e25.","journal-title":"Cell"},{"key":"1892_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217219","volume":"604","author":"MR Chica-Parrado","year":"2024","unstructured":"Chica-Parrado MR, Kim GM, Uemoto Y, Napolitano F, Lin CC, Ye D, et al. Combined inhibition of CDK4\/6 and AKT is highly effective against the luminal androgen receptor (LAR) subtype of triple-negative breast cancer. Cancer Lett. 2024;604:217219.","journal-title":"Cancer Lett"},{"key":"1892_CR26","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1158\/1078-0432.CCR-19-1773","volume":"26","author":"KE Hutchinson","year":"2020","unstructured":"Hutchinson KE, Yost SE, Chang CW, Johnson RM, Carr AR, McAdam PR, et al. Comprehensive profiling of poor-risk paired primary and recurrent triple-negative breast cancers reveals immune phenotype shifts. Clin Cancer Res. 2020;26:657\u201368.","journal-title":"Clin Cancer Res"},{"key":"1892_CR27","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1158\/2159-8290.CD-18-1177","volume":"9","author":"AC Garrido-Castro","year":"2019","unstructured":"Garrido-Castro AC, Lin NU, Polyak K. Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment. Cancer Discov. 2019;9:176\u201398.","journal-title":"Cancer Discov"},{"key":"1892_CR28","doi-asserted-by":"publisher","first-page":"5505","DOI":"10.1158\/1078-0432.CCR-12-3327","volume":"19","author":"A Gucalp","year":"2013","unstructured":"Gucalp A, Tolaney S, Isakoff SJ, Ingle JN, Liu MC, Carey LA, et al. Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic breast cancer. Clin Cancer Res. 2013;19:5505\u201312.","journal-title":"Clin Cancer Res"},{"key":"1892_CR29","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/s41416-018-0142-6","volume":"119","author":"S Guiu","year":"2018","unstructured":"Guiu S, Mollevi C, Charon-Barra C, Boissi\u00e8re F, Crapez E, Chartron E, et al. Prognostic value of androgen receptor and FOXA1 co-expression in non-metastatic triple-negative breast cancer and correlation with other biomarkers. Br J Cancer. 2018;119:76\u20139.","journal-title":"Br J Cancer"},{"key":"1892_CR30","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1186\/s40425-019-0740-8","volume":"7","author":"L Molinero","year":"2019","unstructured":"Molinero L, Li Y, Chang CW, Maund S, Berg M, Harrison J, et al. Tumor immune microenvironment and genomic evolution in a patient with metastatic triple-negative breast cancer and a complete response to atezolizumab. J Immunother Cancer. 2019;7:274.","journal-title":"J Immunother Cancer"},{"key":"1892_CR31","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1016\/j.annonc.2021.07.007","volume":"32","author":"S Loi","year":"2021","unstructured":"Loi S, Michiels S, Adams S, Loibl S, Budczies J, Denkert C, et al. The journey of tumor-infiltrating lymphocytes as a biomarker in breast cancer: clinical utility in an era of checkpoint inhibition. Ann Oncol. 2021;32:1236\u201344.","journal-title":"Ann Oncol"},{"key":"1892_CR32","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1016\/j.annonc.2021.03.052","volume":"32","author":"JS Prabhu","year":"2021","unstructured":"Prabhu JS, Patil S, Rajarajan S, Ce A, Nair M, Alexander A, et al. Triple-negative breast cancers with expression of glucocorticoid receptor in immune cells show better prognosis. Ann Oncol. 2021;32:S35.","journal-title":"Ann Oncol"},{"key":"1892_CR33","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1093\/annonc\/mdv571","volume":"27","author":"G Pruneri","year":"2016","unstructured":"Pruneri G, Vingiani A, Bagnardi V, Rotmensz N, De Rose A, Palazzo A, et al. Clinical validity of tumor-infiltrating lymphocytes analysis in patients with triple-negative breast cancer. Ann Oncol. 2016;27:249\u201356.","journal-title":"Ann Oncol"},{"key":"1892_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.114751","volume":"43","author":"C Caggiano","year":"2024","unstructured":"Caggiano C, Petrera V, Ferri M, Pieraccioli M, Cesari E, Di Leone A, et al. Transient splicing inhibition causes persistent DNA damage and chemotherapy vulnerability in triple-negative breast cancer. Cell Rep. 2024;43:114751.","journal-title":"Cell Rep"},{"key":"1892_CR35","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.neo.2018.03.003","volume":"20","author":"J Jin","year":"2018","unstructured":"Jin J, Fang H, Yang F, Ji W, Guan N, Sun Z, et al. Combined inhibition of ATR and WEE1 as a novel therapeutic strategy in triple-negative breast cancer. Neoplasia. 2018;20:478\u201388.","journal-title":"Neoplasia"},{"key":"1892_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2023.115449","volume":"209","author":"L Fu","year":"2023","unstructured":"Fu L, Li Z, Ren Y, Yu H, Liu B, Qiu Y. CRISPR\/Cas genome editing in triple-negative breast cancer: current situation and future directions. Biochem Pharmacol. 2023;209:115449.","journal-title":"Biochem Pharmacol"},{"key":"1892_CR37","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.3390\/biomedicines9111512","volume":"9","author":"DD Singh","year":"2021","unstructured":"Singh DD, Parveen A, Yadav DK. Role of PARP in TNBC: mechanism of inhibition, clinical applications, and resistance. Biomedicines. 2021;9:1512.","journal-title":"Biomedicines"},{"key":"1892_CR38","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1038\/s41416-023-02226-w","volume":"128","author":"M Beniey","year":"2023","unstructured":"Beniey M, Hubert A, Haque T, Cotte AK, B\u00e9chir N, Zhang X, et al. Sequential targeting of PARP with carboplatin inhibits primary tumour growth and distant metastasis in triple-negative breast cancer. Br J Cancer. 2023;128:1964\u201375.","journal-title":"Br J Cancer"},{"key":"1892_CR39","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.3390\/ph14121270","volume":"14","author":"M Yordanova","year":"2021","unstructured":"Yordanova M, Hubert A, Hassan S. Expanding the use of PARP inhibitors as monotherapy and in combination in triple-negative breast cancer. Pharmaceuticals. 2021;14:1270.","journal-title":"Pharmaceuticals"},{"key":"1892_CR40","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s13046-021-01930-w","volume":"40","author":"X Zhu","year":"2021","unstructured":"Zhu X, Chen L, Huang B, Li X, Yang L, Hu X, et al. Efficacy and mechanism of the combination of PARP and CDK4\/6 inhibitors in the treatment of triple-negative breast cancer. J Exp Clin Cancer Res. 2021;40:122.","journal-title":"J Exp Clin Cancer Res"},{"key":"1892_CR41","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1136\/gutjnl-2019-319984","volume":"70","author":"L Perkhofer","year":"2021","unstructured":"Perkhofer L, Gout J, Roger E, Kude de Almeida F, Baptista Sim\u00f5es C, Wiesm\u00fcller L, et al. DNA damage repair as a target in pancreatic cancer: state-of-the-art and future perspectives. Gut. 2021;70:606\u201317.","journal-title":"Gut"},{"key":"1892_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-53877-z","volume":"15","author":"L Espinar","year":"2024","unstructured":"Espinar L, Garc\u00eda-Cao M, Schmidt A, Kourtis S, Ga\u00f1ez Zapater A, Aranda-Vallejo C, et al. Nuclear IMPDH2 controls the DNA damage response by modulating PARP1 activity. Nat Commun. 2024;15:9515.","journal-title":"Nat Commun"},{"key":"1892_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-023-00568-5","volume":"9","author":"ZL Teo","year":"2023","unstructured":"Teo ZL, O\u2019Connor MJ, Versaci S, Clarke KA, Brown ER, Percy LW, et al. Combined PARP and WEE1 inhibition triggers anti-tumor immune response in BRCA1\/2 wildtype triple-negative breast cancer. NPJ Breast Cancer. 2023;9:68.","journal-title":"NPJ Breast Cancer"},{"key":"1892_CR44","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1093\/annonc\/mdz012","volume":"30","author":"ME Robson","year":"2019","unstructured":"Robson ME, Tung N, Conte P, Im SA, Senkus E, Xu B, et al. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician\u2019s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol. 2019;30:558\u201366.","journal-title":"Ann Oncol"},{"key":"1892_CR45","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1093\/oncolo\/oyad139","volume":"28","author":"JK Litton","year":"2023","unstructured":"Litton JK, Beck JT, Jones JM, Andersen J, Blum JL, Mina LA, et al. Neoadjuvant talazoparib in patients with germline BRCA1\/2 mutation-positive, early-stage triple-negative breast cancer: results of a phase II study. Oncologist. 2023;28:845\u201355.","journal-title":"Oncologist"},{"key":"1892_CR46","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1038\/s43018-022-00400-2","volume":"3","author":"LM Spring","year":"2022","unstructured":"Spring LM, Han H, Liu MC, Hamilton E, Irie H, Santa-Maria CA, et al. Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer. Nat Cancer. 2022;3:927\u201331.","journal-title":"Nat Cancer"},{"key":"1892_CR47","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1007\/s40262-022-01167-6","volume":"61","author":"MAC Bruin","year":"2022","unstructured":"Bruin MAC, Sonke GS, Beijnen JH, Huitema ADR. Pharmacokinetics and pharmacodynamics of PARP inhibitors in oncology. Clin Pharmacokinet. 2022;61:1649\u201375.","journal-title":"Clin Pharmacokinet"},{"key":"1892_CR48","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S1470-2045(18)30111-6","volume":"19","author":"S Loibl","year":"2018","unstructured":"Loibl S, O\u2019Shaughnessy J, Untch M, Sikov WM, Rugo HS, McKee MD, et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncol. 2018;19:497\u2013509.","journal-title":"Lancet Oncol"},{"key":"1892_CR49","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1093\/oncolo\/oyad021","volume":"28","author":"KMZ Savill","year":"2023","unstructured":"Savill KMZ, Ivanova J, Asgarisabet P, Falkenstein A, Balanean A, Niyazov A, et al. Characteristics, treatment, and outcomes of real-world talazoparib-treated patients with germline BRCA-mutated advanced HER2-negative breast cancer. Oncologist. 2023;28:414\u201324.","journal-title":"Oncologist"},{"key":"1892_CR50","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1002\/ijc.34525","volume":"153","author":"E Senkus","year":"2023","unstructured":"Senkus E, Delaloge S, Domchek SM, Conte P, Im SA, Xu B, et al. Olaparib efficacy in patients with germline BRCA-mutated, HER2-negative metastatic breast cancer: subgroup analyses from the phase III OlympiAD trial. Int J Cancer. 2023;153:803\u201314.","journal-title":"Int J Cancer"},{"key":"1892_CR51","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ejca.2023.01.031","volume":"184","author":"ME Robson","year":"2023","unstructured":"Robson ME, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, et al. OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician\u2019s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Eur J Cancer. 2023;184:39\u201347.","journal-title":"Eur J Cancer"},{"key":"1892_CR52","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1056\/NEJMoa1802905","volume":"379","author":"JK Litton","year":"2018","unstructured":"Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gon\u00e7alves A, Lee KH, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018;379:753\u201363.","journal-title":"N Engl J Med"},{"key":"1892_CR53","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1093\/annonc\/mdy257","volume":"29","author":"J Ettl","year":"2018","unstructured":"Ettl J, Quek RGW, Lee KH, Rugo HS, Hurvitz S, Gon\u00e7alves A, et al. Quality of life with talazoparib versus physician\u2019s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1\/2 mutation: patient-reported outcomes from the EMBRACA phase III trial. Ann Oncol. 2018;29:1939\u201347.","journal-title":"Ann Oncol"},{"key":"1892_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-66018-5","volume":"10","author":"DH Ha","year":"2020","unstructured":"Ha DH, Min A, Kim S, Jang H, Kim SH, Kim HJ, et al. Antitumor effect of a WEE1 inhibitor and potentiation of olaparib sensitivity by DNA damage response modulation in triple-negative breast cancer. Sci Rep. 2020;10:9930.","journal-title":"Sci Rep"},{"key":"1892_CR55","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/s41416-024-02935-w","volume":"132","author":"CC Villette","year":"2025","unstructured":"Villette CC, Dupuy N, Brightman FA, Zimmermann A, Lignet F, Zenke FT, et al. Semi-mechanistic efficacy model for PARP\u2009+\u2009ATR inhibitors-application to rucaparib and talazoparib in combination with gartisertib in breast cancer PDXs. Br J Cancer. 2025;132:481\u201391.","journal-title":"Br J Cancer"},{"key":"1892_CR56","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1001\/jamaoncol.2022.5228","volume":"9","author":"TA Yap","year":"2023","unstructured":"Yap TA, Bardia A, Dvorkin M, Galsky MD, Beck JT, Wise DR, et al. Avelumab plus talazoparib in patients with advanced solid tumors: the JAVELIN PARP medley nonrandomized controlled trial. JAMA Oncol. 2023;9:40\u201350.","journal-title":"JAMA Oncol"},{"key":"1892_CR57","doi-asserted-by":"publisher","first-page":"719","DOI":"10.3390\/cancers12030719","volume":"12","author":"TM Pitts","year":"2020","unstructured":"Pitts TM, Simmons DM, Bagby SM, Hartman SJ, Yacob BW, Gittleman B, et al. Wee1 inhibition enhances the anti-tumor effects of capecitabine in preclinical models of triple-negative breast cancer. Cancers. 2020;12:719.","journal-title":"Cancers"},{"key":"1892_CR58","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1080\/13543784.2022.2067527","volume":"31","author":"L Luo","year":"2022","unstructured":"Luo L, Keyomarsi K. PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers. Expert Opin Investig Drugs. 2022;31:607\u201331.","journal-title":"Expert Opin Investig Drugs"},{"key":"1892_CR59","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-025-02063-0","volume":"27","author":"S Ryu","year":"2025","unstructured":"Ryu S, Kim HS, Lee S, Yoon SH, Baek M, Park AY, et al. Anti-cancer drug sensitivity testing and preclinical evaluation of the anti-cancer potential of WEE1 inhibitor in triple-negative breast cancer patient-derived organoids and xenograft models. Breast Cancer Res. 2025;27:113.","journal-title":"Breast Cancer Res"},{"key":"1892_CR60","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1101\/gad.214080.113","volume":"27","author":"FB Couch","year":"2013","unstructured":"Couch FB, Bansbach CE, Driscoll R, Luzwick JW, Glick GG, B\u00e9tous R, et al. ATR phosphorylates SMARCAL1 to prevent replication fork collapse. Genes Dev. 2013;27:1610\u201323.","journal-title":"Genes Dev"},{"key":"1892_CR61","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/nrm2450","volume":"9","author":"KA Cimprich","year":"2008","unstructured":"Cimprich KA, Cortez D. ATR: an essential regulator of genome integrity. Nat Rev Mol Cell Biol. 2008;9:616\u201327.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1892_CR62","doi-asserted-by":"publisher","first-page":"16090","DOI":"10.1073\/pnas.1005031107","volume":"107","author":"E Petermann","year":"2010","unstructured":"Petermann E, Woodcock M, Helleday T. Chk1 promotes replication fork progression by controlling replication initiation. Proc Natl Acad Sci USA. 2010;107:16090\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1892_CR63","doi-asserted-by":"publisher","first-page":"4371","DOI":"10.1200\/JCO.2016.67.5991","volume":"34","author":"S Leijen","year":"2016","unstructured":"Leijen S, van Geel RM, Pavlick AC, Tibes R, Rosen L, Razak AR, et al. Phase I study evaluating WEE1 inhibitor AZD1775 as monotherapy and in combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors. J Clin Oncol. 2016;34:4371\u201380.","journal-title":"J Clin Oncol"},{"key":"1892_CR64","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.1158\/1078-0432.CCR-16-2273","volume":"23","author":"H Kim","year":"2017","unstructured":"Kim H, George E, Ragland R, Rafail S, Zhang R, Krepler C, et al. Targeting the ATR\/CHK1 axis with PARP inhibition results in tumor regression in BRCA-mutant ovarian cancer models. Clin Cancer Res. 2017;23:3097\u2013108.","journal-title":"Clin Cancer Res"},{"key":"1892_CR65","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202203884","volume":"10","author":"W Liu","year":"2023","unstructured":"Liu W, Zheng M, Zhang R, Jiang Q, Du G, Wu Y, et al. RNF126-mediated MRE11 ubiquitination activates the DNA damage response and confers resistance of triple-negative breast cancer to radiotherapy. Adv Sci. 2023;10:e2203884.","journal-title":"Adv Sci"},{"key":"1892_CR66","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s11523-023-00965-7","volume":"18","author":"TM Bauer","year":"2023","unstructured":"Bauer TM, Moore KN, Rader JS, Simpkins F, Mita AC, Beck JT, et al. A phase Ib study assessing the safety, tolerability, and efficacy of the first-in-class wee1 inhibitor adavosertib (AZD1775) as monotherapy in patients with advanced solid tumors. Target Oncol. 2023;18:517\u201330.","journal-title":"Target Oncol"},{"key":"1892_CR67","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1158\/0008-5472.CAN-21-2997","volume":"82","author":"Z Wilson","year":"2022","unstructured":"Wilson Z, Odedra R, Wallez Y, Wijnhoven PWG, Hughes AM, Gerrard J, et al. ATR inhibitor AZD6738 (Ceralasertib) exerts antitumor activity as a monotherapy and in combination with chemotherapy and the PARP inhibitor olaparib. Cancer Res. 2022;82:1140\u201352.","journal-title":"Cancer Res"},{"key":"1892_CR68","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/nchembio.573","volume":"7","author":"PM Reaper","year":"2011","unstructured":"Reaper PM, Griffiths MR, Long JM, Charrier JD, Maccormick S, Charlton PA, et al. Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR. Nat Chem Biol. 2011;7:428\u201330.","journal-title":"Nat Chem Biol"},{"key":"1892_CR69","doi-asserted-by":"publisher","DOI":"10.1172\/JCI175369","volume":"134","author":"MT Dillon","year":"2024","unstructured":"Dillon MT, Guevara J, Mohammed K, Patin EC, Smith SA, Dean E, et al. Durable responses to ATR inhibition with ceralasertib in tumors with genomic defects and high inflammation. J Clin Invest. 2024;134:e175369.","journal-title":"J Clin Invest"},{"key":"1892_CR70","doi-asserted-by":"publisher","first-page":"4751","DOI":"10.1158\/1078-0432.CCR-23-1696","volume":"29","author":"A Ring","year":"2023","unstructured":"Ring A, Kilburn LS, Pearson A, Moretti L, Afshari-Mehr A, Wardley AM, et al. Olaparib and ceralasertib (AZD6738) in patients with triple-negative advanced breast cancer: results from cohort e of the plasmaMATCH trial (CRUK\/15\/010). Clin Cancer Res. 2023;29:4751\u20139.","journal-title":"Clin Cancer Res"},{"key":"1892_CR71","first-page":"566","volume":"60","author":"JR Jackson","year":"2000","unstructured":"Jackson JR, Gilmartin A, Imburgia C, Winkler JD, Marshall LA, Roshak A. An indolocarbazole inhibitor of human checkpoint kinase (Chk1) abrogates cell cycle arrest caused by DNA damage. Cancer Res. 2000;60:566\u201372.","journal-title":"Cancer Res"},{"key":"1892_CR72","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1552707","volume":"16","author":"Q Wu","year":"2025","unstructured":"Wu Q, Xu J, Tang X, Yu J, Li B, Yang J, et al. SB218078 inhibits angiogenesis and epithelial-mesenchymal transition in breast cancer. Front Pharmacol. 2025;16:1552707.","journal-title":"Front Pharmacol"},{"key":"1892_CR73","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.bcp.2016.01.017","volume":"105","author":"R Preet","year":"2016","unstructured":"Preet R, Siddharth S, Satapathy SR, Das S, Nayak A, Das D, et al. Chk1 inhibitor synergizes quinacrine- mediated apoptosis in breast cancer cells by compromising the base excision repair cascade. Biochem Pharmacol. 2016;105:23\u201333.","journal-title":"Biochem Pharmacol"},{"key":"1892_CR74","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2021.174366","volume":"908","author":"H Zhu","year":"2021","unstructured":"Zhu H, Rao Z, Yuan S, You J, Hong C, He Q, et al. One therapeutic approach for triple-negative breast cancer: Checkpoint kinase 1 inhibitor AZD7762 combination with neoadjuvant carboplatin. Eur J Pharmacol. 2021;908:174366.","journal-title":"Eur J Pharmacol"},{"key":"1892_CR75","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107429","volume":"209","author":"YW Lai","year":"2024","unstructured":"Lai YW, Liu ZW, Lin MH, Yang CC, Chu CY, Chung CH, et al. Melatonin increases Olaparib sensitivity and suppresses cancer-associated fibroblast infiltration via suppressing the LAMB3-CXCL2 axis in TNBC. Pharmacol Res. 2024;209:107429.","journal-title":"Pharmacol Res"},{"key":"1892_CR76","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202306860","volume":"11","author":"Q Deng","year":"2024","unstructured":"Deng Q, Qiang J, Liu C, Ding J, Tu J, He X, et al. SOSTDC1 nuclear translocation facilitates BTIC maintenance and CHD1-mediated HR repair to promote tumor progression and olaparib resistance in TNBC. Adv Sci. 2024;11:e2306860.","journal-title":"Adv Sci"},{"key":"1892_CR77","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/s43018-020-00148-7","volume":"2","author":"AK Mehta","year":"2021","unstructured":"Mehta AK, Cheney EM, Hartl CA, Pantelidou C, Oliwa M, Castrillon JA, et al. Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer. Nat Cancer. 2021;2:66\u201382.","journal-title":"Nat Cancer"},{"key":"1892_CR78","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1158\/2159-8290.CD-18-1218","volume":"9","author":"C Pantelidou","year":"2019","unstructured":"Pantelidou C, Sonzogni O, De Oliveria Taveira M, Mehta AK, Kothari A, Wang D, et al. PARP inhibitor efficacy depends on CD8+ T-cell recruitment via intratumoral STING pathway activation in BRCA-deficient models of triple-negative breast cancer. Cancer Discov. 2019;9:722\u201337.","journal-title":"Cancer Discov"},{"key":"1892_CR79","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1001\/jamaoncol.2019.1029","volume":"5","author":"S Vinayak","year":"2019","unstructured":"Vinayak S, Tolaney SM, Schwartzberg L, Mita M, McCann G, Tan AR, et al. Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer. JAMA Oncol. 2019;5:1132\u201340.","journal-title":"JAMA Oncol"},{"key":"1892_CR80","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1042\/BST20191092","volume":"48","author":"C Sun","year":"2020","unstructured":"Sun C, Fang Y, Labrie M, Li X, Mills GB. Systems approach to rational combination therapy: PARP inhibitors. Biochem Soc Trans. 2020;48:1101\u20138.","journal-title":"Biochem Soc Trans"},{"key":"1892_CR81","doi-asserted-by":"publisher","first-page":"6004","DOI":"10.1158\/0008-5472.CAN-21-1499","volume":"81","author":"R Woitek","year":"2021","unstructured":"Woitek R, McLean MA, Ursprung S, Rueda OM, Manzano Garcia R, Locke MJ, et al. Hyperpolarized carbon-13 MRI for early response assessment of neoadjuvant chemotherapy in breast cancer patients. Cancer Res. 2021;81:6004\u201317.","journal-title":"Cancer Res"},{"key":"1892_CR82","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1038\/s41586-024-07384-2","volume":"629","author":"JE Abraham","year":"2024","unstructured":"Abraham JE, Pinilla K, Dayimu A, Grybowicz L, Demiris N, Harvey C, et al. The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer. Nature. 2024;629:1142\u20138.","journal-title":"Nature"},{"key":"1892_CR83","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-59151-0","volume":"16","author":"JE Abraham","year":"2025","unstructured":"Abraham JE, O\u2019Connor LO, Grybowicz L, Alba KP, Dayimu A, Demiris N, et al. Neoadjuvant PARP inhibitor scheduling in BRCA1 and BRCA2-related breast cancer: PARTNER, a randomized phase II\/III trial. Nat Commun. 2025;16:4269.","journal-title":"Nat Commun"},{"key":"1892_CR84","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1172\/JCI45014","volume":"121","author":"BD Lehmann","year":"2011","unstructured":"Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121:2750\u201367.","journal-title":"J Clin Invest"},{"key":"1892_CR85","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1007\/s11523-024-01102-8","volume":"19","author":"EP Hamilton","year":"2024","unstructured":"Hamilton EP, Falchook GS, Wang JS, Fu S, Oza AM, Imedio ER, et al. Adavosertib in combination with olaparib in patients with refractory solid tumors: an open-label, dose-finding, and dose-expansion phase Ib trial. Target Oncol. 2024;19:879\u201392.","journal-title":"Target Oncol"},{"key":"1892_CR86","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1097\/PPO.0000000000000561","volume":"27","author":"G Smith","year":"2021","unstructured":"Smith G, Alholm Z, Coleman RL, Monk BJ. DNA damage repair inhibitors: combination therapies. Cancer J. 2021;27:501\u20135.","journal-title":"Cancer J"},{"key":"1892_CR87","doi-asserted-by":"publisher","first-page":"803","DOI":"10.3390\/genes13050803","volume":"13","author":"J Li","year":"2022","unstructured":"Li J, Lan M, Peng J, Xiong Q, Xu Y, Yang Y, et al. Cdh1 deficiency sensitizes TNBC cells to PARP inhibitors. Genes. 2022;13:803.","journal-title":"Genes"},{"key":"1892_CR88","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13045-022-01260-0","volume":"15","author":"M Liao","year":"2022","unstructured":"Liao M, Qin R, Huang W, Zhu HP, Peng F, Han B, et al. Targeting regulated cell death (RCD) with small-molecule compounds in triple-negative breast cancer: a revisited perspective from molecular mechanisms to targeted therapies. J Hematol Oncol. 2022;15:44.","journal-title":"J Hematol Oncol"},{"key":"1892_CR89","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinorgbio.2024.112661","volume":"259","author":"Z Lv","year":"2024","unstructured":"Lv Z, Ali A, Wang N, Ren H, Liu L, Yan F, et al. Co-targeting CDK 4\/6 and C-MYC\/STAT3\/CCND1 axis and inhibition of tumorigenesis and epithelial-mesenchymal transition in triple negative breast cancer by Pt(II) complexes bearing NH3 as trans-co-ligand. J Inorg Biochem. 2024;259:112661.","journal-title":"J Inorg Biochem"},{"key":"1892_CR90","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s13046-022-02362-w","volume":"41","author":"X Li","year":"2022","unstructured":"Li X, Li J, Xu L, Wei W, Cheng A, Zhang L, et al. CDK16 promotes the progression and metastasis of triple-negative breast cancer by phosphorylating PRC1. J Exp Clin Cancer Res. 2022;41:149.","journal-title":"J Exp Clin Cancer Res"},{"key":"1892_CR91","doi-asserted-by":"publisher","DOI":"10.1172\/JCI188839","volume":"135","author":"S Kim","year":"2025","unstructured":"Kim S, Son E, Park HR, Kim M, Yang HW. Dual targeting CDK4\/6 and CDK7 augments tumor response and anti-tumor immunity in breast cancer models. J Clin Invest. 2025;135:e188839.","journal-title":"J Clin Invest"},{"key":"1892_CR92","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2025.117367","volume":"287","author":"J Huang","year":"2025","unstructured":"Huang J, He Y, Chen S, Ren R, Zhang S, Zhang JQ, et al. Design, synthesis and biological evaluation of dual CDK9\/PARP inhibitors for the treatment of cancer. Eur J Med Chem. 2025;287:117367.","journal-title":"Eur J Med Chem"},{"key":"1892_CR93","doi-asserted-by":"publisher","first-page":"4353","DOI":"10.3390\/cancers14184353","volume":"14","author":"VE van der Noord","year":"2022","unstructured":"van der Noord VE, van de Water B, Le D\u00e9v\u00e9dec SE. Targeting the heterogeneous genomic landscape in triple-negative breast cancer through inhibitors of the transcriptional machinery. Cancers. 2022;14:4353.","journal-title":"Cancers"},{"key":"1892_CR94","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104324","volume":"196","author":"R Gerosa","year":"2024","unstructured":"Gerosa R, De Sanctis R, Jacobs F, Benvenuti C, Gaudio M, Saltalamacchia G, et al. Cyclin-dependent kinase 2 (CDK2) inhibitors and others novel CDK inhibitors (CDKi) in breast cancer: clinical trials, current impact, and future directions. Crit Rev Oncol Hematol. 2024;196:104324.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1892_CR95","doi-asserted-by":"publisher","first-page":"4760","DOI":"10.1158\/1078-0432.CCR-15-1185","volume":"21","author":"JA Beaver","year":"2015","unstructured":"Beaver JA, Amiri-Kordestani L, Charlab R, Chen W, Palmby T, Tilley A, et al. FDA approval: Palbociclib for the treatment of postmenopausal patients with estrogen receptor-positive, HER2-negative metastatic breast cancer. Clin Cancer Res. 2015;21:4760\u20136.","journal-title":"Clin Cancer Res"},{"key":"1892_CR96","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1158\/1078-0432.CCR-17-2369","volume":"24","author":"A Shah","year":"2018","unstructured":"Shah A, Bloomquist E, Tang S, Fu W, Bi Y, Liu Q, et al. FDA approval: Ribociclib for the treatment of postmenopausal women with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer. Clin Cancer Res. 2018;24:2999\u20133004.","journal-title":"Clin Cancer Res"},{"key":"1892_CR97","doi-asserted-by":"crossref","unstructured":"Raheem F, Ofori H, Simpson L, Shah V. Abemaciclib: the first FDA-approved CDK4\/6 inhibitor for the adjuvant treatment of HR+HER2- early breast cancer. Ann Pharmacother. 2022;56:1258\u201366.","DOI":"10.1177\/10600280211073322"},{"key":"1892_CR98","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202305142","volume":"11","author":"T Xia","year":"2024","unstructured":"Xia T, Dai XY, Sang MY, Zhang X, Xu F, Wu J, et al. IGF2BP2 drives cell cycle progression in triple-negative breast cancer by recruiting EIF4A1 to promote the m6A-modified CDK6 translation initiation process. Adv Sci. 2024;11:e2305142.","journal-title":"Adv Sci"},{"key":"1892_CR99","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1002\/mco2.97","volume":"2","author":"L Saleh","year":"2021","unstructured":"Saleh L, Wilson C, Holen I. CDK4\/6 inhibitors: A potential therapeutic approach for triple-negative breast cancer. MedComm. 2021;2:514\u201330.","journal-title":"MedComm"},{"key":"1892_CR100","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1080\/14656566.2020.1838485","volume":"22","author":"GT Gallanis","year":"2021","unstructured":"Gallanis GT, Pericas RI, Riegel AT, Pohlmann PR. An evaluation of palbociclib as a breast cancer treatment option: a current update. Expert Opin Pharmacother. 2021;22:281\u201390.","journal-title":"Expert Opin Pharmacother"},{"key":"1892_CR101","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-020-01597-x","volume":"20","author":"Y Huang","year":"2020","unstructured":"Huang Y, Wu H, Li X. Novel sequential treatment with palbociclib enhances the effect of cisplatin in RB-proficient triple-negative breast cancer. Cancer Cell Int. 2020;20:501.","journal-title":"Cancer Cell Int"},{"key":"1892_CR102","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s40262-022-01206-2","volume":"62","author":"Y Ji","year":"2023","unstructured":"Ji Y, Yartsev V, Quinlan M, Serra P, Wang Y, Chakraborty A, et al. Justifying Ribociclib dose in patients with advanced breast cancer with renal impairment based on PK, safety, and efficacy data: an innovative approach integrating data from a dedicated renal impairment study and oncology clinical trials. Clin Pharmacokinet. 2023;62:493\u2013504.","journal-title":"Clin Pharmacokinet"},{"key":"1892_CR103","doi-asserted-by":"publisher","first-page":"4177","DOI":"10.1158\/1078-0432.CCR-20-2114","volume":"27","author":"A Bardia","year":"2021","unstructured":"Bardia A, Hurvitz SA, DeMichele A, Clark AS, Zelnak A, Yardley DA, et al. Phase I\/II trial of exemestane, ribociclib, and everolimus in women with HR+\/HER2- advanced breast cancer after progression on CDK4\/6 inhibitors (TRINITI-1). Clin Cancer Res. 2021;27:4177\u201385.","journal-title":"Clin Cancer Res"},{"key":"1892_CR104","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16170-3","volume":"11","author":"JY Ge","year":"2020","unstructured":"Ge JY, Shu S, Kwon M, Jovanovi\u0107 B, Murphy K, Gulvady A, et al. Acquired resistance to combined BET and CDK4\/6 inhibition in triple-negative breast cancer. Nat Commun. 2020;11:2350.","journal-title":"Nat Commun"},{"key":"1892_CR105","doi-asserted-by":"publisher","first-page":"7186","DOI":"10.1021\/acs.jmedchem.0c00456","volume":"63","author":"Y Li","year":"2020","unstructured":"Li Y, Zhao J, Gutgesell LM, Shen Z, Ratia K, Dye K, et al. Novel pyrrolopyridone bromodomain and extra-terminal motif (BET) inhibitors effective in endocrine-resistant ER+ breast cancer with acquired resistance to fulvestrant and palbociclib. J Med Chem. 2020;63:7186\u2013210.","journal-title":"J Med Chem"},{"key":"1892_CR106","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1038\/s41416-023-02252-8","volume":"128","author":"TA Constantin","year":"2023","unstructured":"Constantin TA, Varela-Carver A, Greenland KK, de Almeida GS, Olden E, Penfold L, et al. The CDK7 inhibitor CT7001 (Samuraciclib) targets proliferation pathways to inhibit advanced prostate cancer. Br J Cancer. 2023;128:2326\u201337.","journal-title":"Br J Cancer"},{"key":"1892_CR107","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2023.104834","volume":"299","author":"KM Piemonte","year":"2023","unstructured":"Piemonte KM, Webb BM, Bobbitt JR, Majmudar PR, Cuellar-Vite L, Bryson BL, et al. Disruption of CDK7 signaling leads to catastrophic chromosomal instability coupled with a loss of condensin-mediated chromatin compaction. J Biol Chem. 2023;299:104834.","journal-title":"J Biol Chem"},{"key":"1892_CR108","doi-asserted-by":"publisher","DOI":"10.1038\/s41389-020-0232-1","volume":"9","author":"L Tang","year":"2020","unstructured":"Tang L, Jin J, Xu K, Wang X, Tang J, Guan X. SOX9 interacts with FOXC1 to activate MYC and regulate CDK7 inhibitor sensitivity in triple-negative breast cancer. Oncogenesis. 2020;9:47.","journal-title":"Oncogenesis"},{"key":"1892_CR109","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40061-y","volume":"14","author":"RC Coombes","year":"2023","unstructured":"Coombes RC, Howell S, Lord SR, Kenny L, Mansi J, Mitri Z, et al. Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib. Nat Commun. 2023;14:4444.","journal-title":"Nat Commun"},{"key":"1892_CR110","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-022-00837-z","volume":"20","author":"Y Wang","year":"2022","unstructured":"Wang Y, Zhang Z, Mi X, Li M, Huang D, Song T, et al. Elevation of effective p53 expression sensitizes wild-type p53 breast cancer cells to CDK7 inhibitor THZ1. Cell Commun Signal. 2022;20:96.","journal-title":"Cell Commun Signal"},{"key":"1892_CR111","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1007\/s10555-020-09885-8","volume":"39","author":"GP Sava","year":"2020","unstructured":"Sava GP, Fan H, Coombes RC, Buluwela L, Ali S. CDK7 inhibitors as anticancer drugs. Cancer Metastasis Rev. 2020;39:805\u201323.","journal-title":"Cancer Metastasis Rev"},{"key":"1892_CR112","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216820","volume":"589","author":"E Orhan","year":"2024","unstructured":"Orhan E, Velazquez C, Tabet I, Fenou L, Rodier G, Orsetti B, et al. CDK inhibition results in pharmacologic BRCAness increasing sensitivity to olaparib in BRCA1-WT and olaparib-resistant in triple negative breast cancer. Cancer Lett. 2024;589:216820.","journal-title":"Cancer Lett"},{"key":"1892_CR113","doi-asserted-by":"publisher","first-page":"e0234103","DOI":"10.1371\/journal.pone.0234103","volume":"15","author":"S Frame","year":"2020","unstructured":"Frame S, Saladino C, MacKay C, Atrash B, Sheldrake P, McDonald E, et al. Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer. PLoS One. 2020;15:e0234103.","journal-title":"PLoS One"},{"key":"1892_CR114","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.13730","volume":"57","author":"T Rossi","year":"2024","unstructured":"Rossi T, Iorio E, Chirico M, Pisanu ME, Amodio N, Cantafio MEG, et al. BET inhibitors (BETi) influence oxidative phosphorylation metabolism by affecting mitochondrial dynamics leading to alterations in apoptotic pathways in triple-negative breast cancer (TNBC) cells. Cell Prolif. 2024;57:e13730.","journal-title":"Cell Prolif"},{"key":"1892_CR115","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-021-01038-6","volume":"23","author":"E Agostinetto","year":"2021","unstructured":"Agostinetto E, Eiger D, Punie K, de Azambuja E. Emerging therapeutics for patients with triple-negative breast cancer. Curr Oncol Rep. 2021;23:57.","journal-title":"Curr Oncol Rep"},{"key":"1892_CR116","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1016\/j.ccell.2021.08.009","volume":"39","author":"K Freeman-Cook","year":"2021","unstructured":"Freeman-Cook K, Hoffman RL, Miller N, Almaden J, Chionis J, Zhang Q, et al. Expanding control of the tumor cell cycle with a CDK2\/4\/6 inhibitor. Cancer Cell. 2021;39:1404\u201321.e11.","journal-title":"Cancer Cell"},{"key":"1892_CR117","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/nature16508","volume":"529","author":"S Shu","year":"2016","unstructured":"Shu S, Lin CY, He HH, Witwicki RM, Tabassum DP, Roberts JM, et al. Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer. Nature. 2016;529:413\u20137.","journal-title":"Nature"},{"key":"1892_CR118","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1002\/ijc.31898","volume":"144","author":"C Mio","year":"2019","unstructured":"Mio C, Gerratana L, Bolis M, Caponnetto F, Zanello A, Barbina M, et al. BET proteins regulate homologous recombination-mediated DNA repair: BRCAness and implications for cancer therapy. Int J Cancer. 2019;144:755\u201366.","journal-title":"Int J Cancer"},{"key":"1892_CR119","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107377","volume":"208","author":"N Liu","year":"2024","unstructured":"Liu N, Wang S, Li M, Zhao N, Wang D, Zhang R, et al. BET degrader exhibits lower antiproliferative activity than its inhibitor via EGR1 recruiting septins to promote E2F1-3 transcription in triple-negative breast cancer. Pharmacol Res. 2024;208:107377.","journal-title":"Pharmacol Res"},{"key":"1892_CR120","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1158\/0008-5472.CAN-16-2622","volume":"77","author":"L Bai","year":"2017","unstructured":"Bai L, Zhou B, Yang CY, Ji J, McEachern D, Przybranowski S, et al. Targeted degradation of BET proteins in triple-negative breast cancer. Cancer Res. 2017;77:2476\u201387.","journal-title":"Cancer Res"},{"key":"1892_CR121","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1016\/j.molcel.2020.04.027","volume":"78","author":"S Shu","year":"2020","unstructured":"Shu S, Wu HJ, Ge JY, Zeid R, Harris IS, Jovanovi\u0107 B, et al. Synthetic lethal and resistance interactions with BET bromodomain inhibitors in triple-negative breast cancer. Mol Cell. 2020;78:1096\u2013113.e8.","journal-title":"Mol Cell"},{"key":"1892_CR122","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aba8968","volume":"6","author":"N Verma","year":"2020","unstructured":"Verma N, Vinik Y, Saroha A, Nair NU, Ruppin E, Mills G, et al. Synthetic lethal combination targeting BET uncovered intrinsic susceptibility of TNBC to ferroptosis. Sci Adv. 2020;6:eaba8968.","journal-title":"Sci Adv"},{"key":"1892_CR123","doi-asserted-by":"publisher","first-page":"e186","DOI":"10.1016\/S2352-3026(15)00247-1","volume":"3","author":"C Berthon","year":"2016","unstructured":"Berthon C, Raffoux E, Thomas X, Vey N, Gomez-Roca C, Yee K, et al. Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study. Lancet Haematol. 2016;3:e186\u201395.","journal-title":"Lancet Haematol"},{"key":"1892_CR124","doi-asserted-by":"publisher","first-page":"e196","DOI":"10.1016\/S2352-3026(16)00021-1","volume":"3","author":"S Amorim","year":"2016","unstructured":"Amorim S, Stathis A, Gleeson M, Iyengar S, Magarotto V, Leleu X, et al. Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study. Lancet Haematol. 2016;3:e196\u2013204.","journal-title":"Lancet Haematol"},{"key":"1892_CR125","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2024.116408","volume":"226","author":"R Wang","year":"2024","unstructured":"Wang R, Jia S, Chen H, Luo K, Zhang L, Song Y, et al. Antiplatelet drug ticagrelor suppresses triple-negative breast cancer metastasis by targeting PI3K. Biochem Pharmacol. 2024;226:116408.","journal-title":"Biochem Pharmacol"},{"key":"1892_CR126","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s12282-024-01567-5","volume":"31","author":"HP Zhang","year":"2024","unstructured":"Zhang HP, Jiang RY, Zhu JY, Sun KN, Huang Y, Zhou HH, et al. PI3K\/AKT\/mTOR signaling pathway: an important driver and therapeutic target in triple-negative breast cancer. Breast Cancer. 2024;31:539\u201351.","journal-title":"Breast Cancer"},{"key":"1892_CR127","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-019-0846-7","volume":"21","author":"H Ellis","year":"2019","unstructured":"Ellis H, Ma CX. PI3K inhibitors in breast cancer therapy. Curr Oncol Rep. 2019;21:110.","journal-title":"Curr Oncol Rep"},{"key":"1892_CR128","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1200\/JCO.19.00368","volume":"38","author":"P Schmid","year":"2020","unstructured":"Schmid P, Abraham J, Chan S, Wheatley D, Brunt AM, Nemsadze G, et al. Capivasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer: the PAKT trial. J Clin Oncol. 2020;38:423\u201333.","journal-title":"J Clin Oncol"},{"key":"1892_CR129","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-022-03462-z","volume":"20","author":"S Cocco","year":"2022","unstructured":"Cocco S, Leone A, Roca MS, Lombardi R, Piezzo M, Caputo R, et al. Inhibition of autophagy by chloroquine prevents resistance to PI3K\/AKT inhibitors and potentiates their antitumor effect in combination with paclitaxel in triple-negative breast cancer models. J Transl Med. 2022;20:290.","journal-title":"J Transl Med"},{"key":"1892_CR130","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s10549-018-4697-y","volume":"169","author":"RLB Costa","year":"2018","unstructured":"Costa RLB, Han HS, Gradishar WJ. Targeting the PI3K\/AKT\/mTOR pathway in triple-negative breast cancer: a review. Breast Cancer Res Treat. 2018;169:397\u2013406.","journal-title":"Breast Cancer Res Treat"},{"key":"1892_CR131","doi-asserted-by":"publisher","first-page":"4329","DOI":"10.1158\/1078-0432.CCR-24-0465","volume":"30","author":"RA Dent","year":"2024","unstructured":"Dent RA, Kim SB, Oliveira M, Barrios C, O\u2019Shaughnessy J, Isakoff SJ, et al. Ipatasertib plus paclitaxel for patients with PIK3CA\/AKT1\/PTEN-altered locally advanced unresectable or metastatic triple-negative breast cancer in the IPATunity130 phase III trial. Clin Cancer Res. 2024;30:4329\u201338.","journal-title":"Clin Cancer Res"},{"key":"1892_CR132","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1158\/2159-8290.CD-11-0336","volume":"2","author":"A Juvekar","year":"2012","unstructured":"Juvekar A, Burga LN, Hu H, Lunsford EP, Ibrahim YH, Balma\u00f1\u00e0 J, et al. Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer. Cancer Discov. 2012;2:1048\u201363.","journal-title":"Cancer Discov"},{"key":"1892_CR133","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13046-018-0741-3","volume":"37","author":"D Cretella","year":"2018","unstructured":"Cretella D, Ravelli A, Fumarola C, La Monica S, Digiacomo G, Cavazzoni A, et al. The anti-tumor efficacy of CDK4\/6 inhibition is enhanced by the combination with PI3K\/AKT\/mTOR inhibitors through impairment of glucose metabolism in TNBC cells. J Exp Clin Cancer Res. 2018;37:72.","journal-title":"J Exp Clin Cancer Res"},{"key":"1892_CR134","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/S1470-2045(19)30689-8","volume":"21","author":"P Schmid","year":"2020","unstructured":"Schmid P, Rugo HS, Adams S, Schneeweiss A, Barrios CH, Iwata H, et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21:44\u201359.","journal-title":"Lancet Oncol"},{"key":"1892_CR135","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1093\/annonc\/mdz133","volume":"30","author":"J Pascual","year":"2019","unstructured":"Pascual J, Turner NC. Targeting the PI3-kinase pathway in triple-negative breast cancer. Ann Oncol. 2019;30:1051\u201360.","journal-title":"Ann Oncol"},{"key":"1892_CR136","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1631\/jzus.B2200113","volume":"23","author":"S Vtorushin","year":"2022","unstructured":"Vtorushin S, Dulesova A, Krakhmal N. Luminal androgen receptor (LAR) subtype of triple-negative breast cancer: molecular, morphological, and clinical features. J Zhejiang Univ Sci B. 2022;23:617\u201324.","journal-title":"J Zhejiang Univ Sci B"},{"key":"1892_CR137","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.ctrv.2018.06.005","volume":"68","author":"L Gerratana","year":"2018","unstructured":"Gerratana L, Basile D, Buono G, De Placido S, Giuliano M, Minichillo S, et al. Androgen receptor in triple-negative breast cancer: a potential target for the targetless subtype. Cancer Treat Rev. 2018;68:102\u201310.","journal-title":"Cancer Treat Rev"},{"key":"1892_CR138","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1200\/JCO.2016.71.3495","volume":"36","author":"TA Traina","year":"2018","unstructured":"Traina TA, Miller K, Yardley DA, Eakle J, Schwartzberg LS, O\u2019Shaughnessy J, et al. Enzalutamide for the treatment of androgen receptor-expressing triple-negative breast cancer. J Clin Oncol. 2018;36:884\u201390.","journal-title":"J Clin Oncol"},{"key":"1892_CR139","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-05084-1","volume":"13","author":"Y Chen","year":"2022","unstructured":"Chen Y, Zhou Q, Hankey W, Fang X, Yuan F. Second-generation androgen receptor antagonists and challenges in prostate cancer treatment. Cell Death Dis. 2022;13:632.","journal-title":"Cell Death Dis"},{"key":"1892_CR140","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3390\/cancers9030021","volume":"9","author":"B Rahim","year":"2017","unstructured":"Rahim B, O\u2019Regan R. AR signaling in breast cancer. Cancers. 2017;9:21.","journal-title":"Cancers"},{"key":"1892_CR141","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/aps.2014.18","volume":"36","author":"MH Tan","year":"2015","unstructured":"Tan MH, Li J, Xu HE, Melcher K, Yong EL. Androgen receptor: structure, role in prostate cancer and drug discovery. Acta Pharmacol Sin. 2015;36:3\u201323.","journal-title":"Acta Pharmacol Sin"},{"key":"1892_CR142","doi-asserted-by":"publisher","first-page":"233","DOI":"10.3390\/cancers15010233","volume":"15","author":"A Khadela","year":"2022","unstructured":"Khadela A, Chavda VP, Soni S, Megha K, Pandya AJ, Vora L. Anti-androgenic therapies targeting the luminal androgen receptor of a typical triple-negative breast cancer. Cancers. 2022;15:233.","journal-title":"Cancers"},{"key":"1892_CR143","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.17.00075","volume":"1","author":"V Kumar","year":"2017","unstructured":"Kumar V, Yu J, Phan V, Tudor IC, Peterson A, Uppal H. Androgen receptor immunohistochemistry as a companion diagnostic approach to predict clinical response to enzalutamide in triple-negative breast cancer. JCO Precis Oncol. 2017;1:1\u201319.","journal-title":"JCO Precis Oncol"},{"key":"1892_CR144","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1158\/1078-0432.CCR-19-2170","volume":"26","author":"BD Lehmann","year":"2020","unstructured":"Lehmann BD, Abramson VG, Sanders ME, Mayer EL, Haddad TC, Nanda R, et al. TBCRC 032 IB\/II multicenter study: molecular insights to AR antagonist and PI3K inhibitor efficacy in patients with AR(+) metastatic triple-negative breast cancer. Clin Cancer Res. 2020;26:2111\u201323.","journal-title":"Clin Cancer Res"},{"key":"1892_CR145","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1093\/annonc\/mdw067","volume":"27","author":"H Bonnefoi","year":"2016","unstructured":"Bonnefoi H, Grellety T, Tredan O, Saghatchian M, Dalenc F, Mailliez A, et al. A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1). Ann Oncol. 2016;27:812\u20138.","journal-title":"Ann Oncol"},{"key":"1892_CR146","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/S1470-2045(24)00737-X","volume":"26","author":"H Bonnefoi","year":"2025","unstructured":"Bonnefoi H, Lerebours F, Pulido M, Arnedos M, Tredan O, Dalenc F, et al. Darolutamide or capecitabine in triple-negative, androgen receptor-positive, advanced breast cancer (UCBG 3-06 START): a multicentre, non-comparative, randomised, phase 2 trial. Lancet Oncol. 2025;26:355\u201366.","journal-title":"Lancet Oncol"},{"key":"1892_CR147","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s10549-018-4813-z","volume":"171","author":"A Bardia","year":"2018","unstructured":"Bardia A, Gucalp A, DaCosta N, Gabrail N, Danso M, Ali H, et al. Phase 1 study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in women with estrogen receptor-positive or triple-negative breast cancer. Breast Cancer Res Treat. 2018;171:111\u201320.","journal-title":"Breast Cancer Res Treat"},{"key":"1892_CR148","doi-asserted-by":"publisher","first-page":"e103202","DOI":"10.1371\/journal.pone.0103202","volume":"9","author":"R Narayanan","year":"2014","unstructured":"Narayanan R, Ahn S, Cheney MD, Yepuru M, Miller DD, Steiner MS, et al. Selective androgen receptor modulators (SARMs) negatively regulate triple-negative breast cancer growth and epithelial-mesenchymal stem cell signaling. PLoS One. 2014;9:e103202.","journal-title":"PLoS One"},{"key":"1892_CR149","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.7150\/thno.36182","volume":"10","author":"F Coussy","year":"2020","unstructured":"Coussy F, Lavigne M, de Koning L, Botty RE, Nemati F, Naguez A, et al. Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts. Theranostics. 2020;10:1531\u201343.","journal-title":"Theranostics"},{"key":"1892_CR150","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.ccell.2019.02.001","volume":"35","author":"YZ Jiang","year":"2019","unstructured":"Jiang YZ, Ma D, Suo C, Shi J, Xue M, Hu X, et al. Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies. Cancer Cell. 2019;35:428\u201340.e5.","journal-title":"Cancer Cell"},{"key":"1892_CR151","doi-asserted-by":"publisher","first-page":"5367","DOI":"10.1158\/1078-0432.CCR-04-0220","volume":"10","author":"TO Nielsen","year":"2004","unstructured":"Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004;10:5367\u201374.","journal-title":"Clin Cancer Res"},{"key":"1892_CR152","doi-asserted-by":"publisher","first-page":"4616","DOI":"10.1021\/acs.jmedchem.1c01646","volume":"65","author":"CM Abdelmalek","year":"2022","unstructured":"Abdelmalek CM, Hu Z, Kronenberger T, K\u00fcblbeck J, Kinnen FJM, Hesse SS, et al. Gefitinib-tamoxifen hybrid ligands as potent agents against triple-negative breast cancer. J Med Chem. 2022;65:4616\u201332.","journal-title":"J Med Chem"},{"key":"1892_CR153","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06502-2","volume":"15","author":"Y Ma","year":"2024","unstructured":"Ma Y, Fang Z, Zhang H, Qi Y, Mao Y, Zheng J. PDZK1 suppresses TNBC development and sensitizes TNBC cells to erlotinib via the EGFR pathway. Cell Death Dis. 2024;15:199.","journal-title":"Cell Death Dis"},{"key":"1892_CR154","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217008","volume":"597","author":"L Andriani","year":"2024","unstructured":"Andriani L, Ling YX, Yang SY, Zhao Q, Ma XY, Huang MY, et al. Sideroflexin-1 promotes progression and sensitivity to lapatinib in triple-negative breast cancer by inhibiting TOLLIP-mediated autophagic degradation of CIP2A. Cancer Lett. 2024;597:217008.","journal-title":"Cancer Lett"},{"key":"1892_CR155","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-024-01327-2","volume":"16","author":"S Pellecchia","year":"2024","unstructured":"Pellecchia S, Franchini M, Viscido G, Arnese R, Gambardella G. Single-cell lineage tracing reveals clonal dynamics of anti-EGFR therapy resistance in triple-negative breast cancer. Genome Med. 2024;16:55.","journal-title":"Genome Med"},{"key":"1892_CR156","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41416-022-02025-9","volume":"128","author":"G Curigliano","year":"2023","unstructured":"Curigliano G, Shapiro GI, Kristeleit RS, Abdul Razak AR, Leong S, Alsina M, et al. A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer. Br J Cancer. 2023;128:30\u201341.","journal-title":"Br J Cancer"},{"key":"1892_CR157","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1200\/JCO.21.01589","volume":"40","author":"JE Chaft","year":"2022","unstructured":"Chaft JE, Shyr Y, Sepesi B, Forde PM. Preoperative and postoperative systemic therapy for operable non-small-cell lung cancer. J Clin Oncol. 2022;40:546\u201355.","journal-title":"J Clin Oncol"},{"key":"1892_CR158","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2024.108037","volume":"154","author":"SR Shetty","year":"2025","unstructured":"Shetty SR, Kar T, Das A. Epidermal growth factor receptor mutations in breast Cancer: Therapeutic challenges and way forward. Bioorg Chem. 2025;154:108037.","journal-title":"Bioorg Chem"},{"key":"1892_CR159","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1158\/1078-0432.CCR-15-0187","volume":"22","author":"M Sameni","year":"2016","unstructured":"Sameni M, Tovar EA, Essenburg CJ, Chalasani A, Linklater ES, Borgman A, et al. Cabozantinib (XL184) inhibits growth and invasion of preclinical TNBC models. Clin Cancer Res. 2016;22:923\u201334.","journal-title":"Clin Cancer Res"},{"key":"1892_CR160","doi-asserted-by":"publisher","first-page":"973","DOI":"10.4143\/crt.2019.726","volume":"52","author":"TH Weng","year":"2020","unstructured":"Weng TH, Yao MY, Xu XM, Hu CY, Yao SH, Liu YZ, et al. RON and MET Co-overexpression are significant pathological characteristics of poor survival and therapeutic targets of tyrosine kinase inhibitors in triple-negative breast cancer. Cancer Res Treat. 2020;52:973\u201386.","journal-title":"Cancer Res Treat"},{"key":"1892_CR161","doi-asserted-by":"publisher","first-page":"8702","DOI":"10.3390\/ijms23158702","volume":"23","author":"JA L\u00f3pez-Mej\u00eda","year":"2022","unstructured":"L\u00f3pez-Mej\u00eda JA, Tallabs-Utrilla LF, Salazar-Sojo P, Mantilla-Ollarves JC, S\u00e1nchez-Carballido MA, Rocha-Zavaleta L. c-Kit induces migration of triple-negative breast cancer cells and is a promising target for tyrosine kinase inhibitor treatment. Int J Mol Sci. 2022;23:8702.","journal-title":"Int J Mol Sci"},{"key":"1892_CR162","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-04488-9","volume":"13","author":"M Shen","year":"2022","unstructured":"Shen M, Zhang R, Jia W, Zhu Z, Zhao L, Huang G, et al. RNA-binding protein p54(nrb)\/NONO potentiates nuclear EGFR-mediated tumorigenesis of triple-negative breast cancer. Cell Death Dis. 2022;13:42.","journal-title":"Cell Death Dis"},{"key":"1892_CR163","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.bbcan.2018.10.003","volume":"1871","author":"E Tulchinsky","year":"2019","unstructured":"Tulchinsky E, Demidov O, Kriajevska M, Barlev NA, Imyanitov E. EMT: a mechanism for escape from EGFR-targeted therapy in lung cancer. Biochim Biophys Acta Rev Cancer. 2019;1871:29\u201339.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"1892_CR164","first-page":"2103","volume":"9","author":"JC Xuhong","year":"2019","unstructured":"Xuhong JC, Qi XW, Zhang Y, Jiang J. Mechanism, safety and efficacy of three tyrosine kinase inhibitors lapatinib, neratinib and pyrotinib in HER2-positive breast cancer. Am J Cancer Res. 2019;9:2103\u201319.","journal-title":"Am J Cancer Res"},{"key":"1892_CR165","first-page":"11","volume":"15","author":"J Ma","year":"2023","unstructured":"Ma J, Dong C, Cao YZ, Ma BL. Dual target of EGFR and mTOR suppresses triple-negative breast cancer cell growth by regulating the phosphorylation of mTOR downstream proteins. Breast Cancer. 2023;15:11\u201324.","journal-title":"Breast Cancer"},{"key":"1892_CR166","doi-asserted-by":"publisher","first-page":"5686","DOI":"10.3390\/molecules25235686","volume":"25","author":"MA Galv\u00e1n Morales","year":"2020","unstructured":"Galv\u00e1n Morales MA, Barrera Rodr\u00edguez R, Santiago Cruz JR, Ter\u00e1n LM. Overview of new treatments with immunotherapy for breast cancer and a proposal of a combination therapy. Molecules. 2020;25:5686.","journal-title":"Molecules"},{"key":"1892_CR167","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1186\/s13046-023-02866-z","volume":"42","author":"S Kim","year":"2023","unstructured":"Kim S, Park JM, Park S, Jung E, Ko D, Park M, et al. Suppression of TNBC metastasis by doxazosin, a novel dual inhibitor of c-MET\/EGFR. J Exp Clin Cancer Res. 2023;42:292.","journal-title":"J Exp Clin Cancer Res"},{"key":"1892_CR168","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01601-0","volume":"21","author":"S Dong","year":"2022","unstructured":"Dong S, Yousefi H, Savage IV, Okpechi SC, Wright MK, Matossian MD, et al. Ceritinib is a novel triple-negative breast cancer therapeutic agent. Mol Cancer. 2022;21:138.","journal-title":"Mol Cancer"},{"key":"1892_CR169","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2025.108169","volume":"156","author":"T Das","year":"2025","unstructured":"Das T, Bhar S, Ghosh D, Kabi B, Kar K, Chandra A. A promising future for breast cancer therapy with hydroxamic acid-based histone deacetylase inhibitors. Bioorg Chem. 2025;156:108169.","journal-title":"Bioorg Chem"},{"key":"1892_CR170","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2024.116884","volume":"279","author":"A Guadagni","year":"2024","unstructured":"Guadagni A, Barone S, Alfano AI, Pelliccia S, Bello I, Panza E, et al. Tackling triple-negative breast cancer with HDAC inhibitors: 6 is the isoform!. Eur J Med Chem. 2024;279:116884.","journal-title":"Eur J Med Chem"},{"key":"1892_CR171","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2021.119504","volume":"277","author":"MJ Ramaiah","year":"2021","unstructured":"Ramaiah MJ, Tangutur AD, Manyam RR. Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy. Life Sci. 2021;277:119504.","journal-title":"Life Sci"},{"key":"1892_CR172","doi-asserted-by":"publisher","first-page":"667","DOI":"10.3390\/ph15060667","volume":"15","author":"C Maccallini","year":"2022","unstructured":"Maccallini C, Ammazzalorso A, De Filippis B, Fantacuzzi M, Giampietro L, Amoroso R. HDAC inhibitors for the therapy of triple-negative breast cancer. Pharmaceuticals. 2022;15:667.","journal-title":"Pharmaceuticals"},{"key":"1892_CR173","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110417","volume":"120","author":"R Guo","year":"2023","unstructured":"Guo R, Li J, Hu J, Fu Q, Yan Y, Xu S, et al. Combination of epidrugs with immune checkpoint inhibitors in cancer immunotherapy: from theory to therapy. Int Immunopharmacol. 2023;120:110417.","journal-title":"Int Immunopharmacol"},{"key":"1892_CR174","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2022.114462","volume":"238","author":"C Wang","year":"2022","unstructured":"Wang C, Chen X, Liu X, Lu D, Li S, Qu L, et al. Discovery of precision targeting EZH2 degraders for triple-negative breast cancer. Eur J Med Chem. 2022;238:114462.","journal-title":"Eur J Med Chem"},{"key":"1892_CR175","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-35059-x","volume":"13","author":"A Verma","year":"2022","unstructured":"Verma A, Singh A, Singh MP, Nengroo MA, Saini KK, Satrusal SR, et al. EZH2-H3K27me3-mediated KRT14 upregulation promotes TNBC peritoneal metastasis. Nat Commun. 2022;13:7344.","journal-title":"Nat Commun"},{"key":"1892_CR176","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-021-02213-2","volume":"21","author":"R Elango","year":"2021","unstructured":"Elango R, Vishnubalaji R, Shaath H, Alajez NM. Transcriptional alterations of protein-coding and noncoding RNAs in triple-negative breast cancer in response to DNA methyltransferases inhibition. Cancer Cell Int. 2021;21:515.","journal-title":"Cancer Cell Int"},{"key":"1892_CR177","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107205","volume":"204","author":"L Zhou","year":"2024","unstructured":"Zhou L, Yu CW. Epigenetic modulations in triple-negative breast cancer: therapeutic implications for tumor microenvironment. Pharmacol Res. 2024;204:107205.","journal-title":"Pharmacol Res"},{"key":"1892_CR178","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1080\/17474086.2018.1453802","volume":"11","author":"SR Bohl","year":"2018","unstructured":"Bohl SR, Bullinger L, R\u00fccker FG. Epigenetic therapy: azacytidine and decitabine in acute myeloid leukemia. Expert Rev Hematol. 2018;11:361\u201371.","journal-title":"Expert Rev Hematol"},{"key":"1892_CR179","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2024.106767","volume":"197","author":"W Fan","year":"2024","unstructured":"Fan W, Li W, Li L, Qin M, Mao C, Yuan Z, et al. Bifunctional HDAC and DNMT inhibitor induces viral mimicry activates the innate immune response in triple-negative breast cancer. Eur J Pharmacol Sci. 2024;197:106767.","journal-title":"Eur J Pharmacol Sci"},{"key":"1892_CR180","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1186\/s13046-019-1387-5","volume":"38","author":"MDM Noblejas-L\u00f3pez","year":"2019","unstructured":"Noblejas-L\u00f3pez MDM, Nieto-Jim\u00e9nez C, Burgos M, G\u00f3mez-Ju\u00e1rez M, Montero JC, Espar\u00eds-Ogando A, et al. Activity of BET-proteolysis-targeting chimeric (PROTAC) compounds in triple-negative breast cancer. J Exp Clin Cancer Res. 2019;38:383.","journal-title":"J Exp Clin Cancer Res"},{"key":"1892_CR181","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-023-01715-3","volume":"25","author":"D Sharma","year":"2023","unstructured":"Sharma D, Hager CG, Shang L, Tran L, Zhu Y, Ma A, et al. The BET degrader ZBC260 suppresses stemness and tumorigenesis and promotes differentiation in triple-negative breast cancer by disrupting inflammatory signaling. Breast Cancer Res. 2023;25:144.","journal-title":"Breast Cancer Res"},{"key":"1892_CR182","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.21873\/anticanres.17564","volume":"45","author":"J Kim","year":"2025","unstructured":"Kim J, Han Q, Kang BM, Mizuta K, Asano Y, Bouvet M, et al. Combination of recombinant methioninase with rapamycin or chloroquine is synergistic to highly inhibit triple-negative breast cancer cells in vitro. Anticancer Res. 2025;45:1853\u20139.","journal-title":"Anticancer Res"},{"key":"1892_CR183","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.canlet.2016.04.002","volume":"376","author":"DH Liang","year":"2016","unstructured":"Liang DH, Choi DS, Ensor JE, Kaipparettu BA, Bass BL, Chang JC. The autophagy inhibitor chloroquine targets cancer stem cells in triple-negative breast cancer by inducing mitochondrial damage and impairing DNA break repair. Cancer Lett. 2016;376:249\u201358.","journal-title":"Cancer Lett"},{"key":"1892_CR184","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-2393-z","volume":"16","author":"G Bouchard","year":"2016","unstructured":"Bouchard G, Therriault H, Geha S, B\u00e9rub\u00e9-Lauzi\u00e8re Y, Bujold R, Saucier C, et al. Stimulation of triple- negative breast cancer cell migration and metastases formation is prevented by chloroquine in a pre-irradiated mouse model. BMC Cancer. 2016;16:361.","journal-title":"BMC Cancer"},{"key":"1892_CR185","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1186\/s13046-018-0967-0","volume":"37","author":"IC Salaroglio","year":"2018","unstructured":"Salaroglio IC, Gazzano E, Abdullrahman A, Mungo E, Castella B, Abd-Elrahman G, et al. Increasing intratumor C\/EBP-\u03b2 LIP and nitric oxide levels overcomes resistance to doxorubicin in triple-negative breast cancer. J Exp Clin Cancer Res. 2018;37:286.","journal-title":"J Exp Clin Cancer Res"},{"key":"1892_CR186","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1111\/cas.13059","volume":"107","author":"W Guo","year":"2016","unstructured":"Guo W, Wang Y, Wang Z, Wang YP, Zheng H. Inhibiting autophagy increases epirubicin\u2019s cytotoxicity in breast cancer cells. Cancer Sci. 2016;107:1610\u201321.","journal-title":"Cancer Sci"},{"key":"1892_CR187","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1247\/csf.23.33","volume":"23","author":"A Yamamoto","year":"1998","unstructured":"Yamamoto A, Tagawa Y, Yoshimori T, Moriyama Y, Masaki R, Tashiro Y. Bafilomycin A1 prevents maturation of autophagic vacuoles by inhibiting fusion between autophagosomes and lysosomes in rat hepatoma cell line, H-4-II-E cells. Cell Struct Funct. 1998;23:33\u201342.","journal-title":"Cell Struct Funct"},{"key":"1892_CR188","doi-asserted-by":"publisher","DOI":"10.1038\/srep37052","volume":"6","author":"Y Yan","year":"2016","unstructured":"Yan Y, Jiang K, Liu P, Zhang X, Dong X, Gao J, et al. Bafilomycin A1 induces caspase-independent cell death in hepatocellular carcinoma cells via targeting of autophagy and MAPK pathways. Sci Rep. 2016;6:37052.","journal-title":"Sci Rep"},{"key":"1892_CR189","doi-asserted-by":"publisher","first-page":"14609","DOI":"10.1021\/acs.jmedchem.0c00873","volume":"63","author":"H Ren","year":"2020","unstructured":"Ren H, Bakas NA, Vamos M, Chaikuad A, Limpert AS, Wimer CD, et al. Design, synthesis, and characterization of an orally active dual-specific ULK1\/2 autophagy inhibitor that synergizes with the PARP inhibitor Olaparib for the treatment of triple-negative breast cancer. J Med Chem. 2020;63:14609\u201325.","journal-title":"J Med Chem"},{"key":"1892_CR190","doi-asserted-by":"publisher","first-page":"53654","DOI":"10.1021\/acsami.0c15089","volume":"12","author":"P Liu","year":"2020","unstructured":"Liu P, Liu X, Cheng Y, Zhong S, Shi X, Wang S, et al. Core-shell nanosystems for self-activated drug-gene combinations against triple-negative breast cancer. ACS Appl Mater Interfaces. 2020;12:53654\u201364.","journal-title":"ACS Appl Mater Interfaces"},{"key":"1892_CR191","doi-asserted-by":"publisher","first-page":"2687","DOI":"10.1039\/C6SC05368H","volume":"8","author":"L Zhang","year":"2017","unstructured":"Zhang L, Fu L, Zhang S, Zhang J, Zhao Y, Zheng Y, et al. Discovery of a small molecule targeting ULK1-modulated cell death of triple-negative breast cancer in vitro and in vivo. Chem Sci. 2017;8:2687\u2013701.","journal-title":"Chem Sci"},{"key":"1892_CR192","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1080\/15548627.2019.1582951","volume":"15","author":"CH Chang","year":"2019","unstructured":"Chang CH, Bijian K, Wernic D, Su J, da Silva SD, Yu H, et al. A novel orally available seleno-purine molecule suppresses triple-negative breast cancer cell proliferation and progression to metastasis by inducing cytostatic autophagy. Autophagy. 2019;15:1376\u201390.","journal-title":"Autophagy"},{"key":"1892_CR193","doi-asserted-by":"publisher","first-page":"606","DOI":"10.3389\/fphar.2020.00606","volume":"11","author":"X Chen","year":"2020","unstructured":"Chen X, Li S, Li D, Li M, Su Z, Lai X, et al. Ethanol extract of Brucea javanica seed inhibits triple-negative breast cancer by restraining autophagy via PI3K\/Akt\/mTOR pathway. Front Pharmacol. 2020;11:606.","journal-title":"Front Pharmacol"},{"key":"1892_CR194","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1080\/15548627.2025.2479995","volume":"21","author":"D Chen","year":"2025","unstructured":"Chen D, Chen X, Yang M, Li Q, Weng S, Kou S, et al. H3K36me2 methyltransferase NSD2\/WHSC1 promotes triple-negative breast cancer metastasis via activation of ULK1-dependent autophagy. Autophagy. 2025;21:1824\u201342.","journal-title":"Autophagy"},{"key":"1892_CR195","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115164","volume":"165","author":"X Yang","year":"2023","unstructured":"Yang X, Yang R, Zhang Y, Shi Y, Ma M, Li F, et al. Xianlinglianxiafang Inhibited the growth and metastasis of triple-negative breast cancer via activating PPAR\u03b3\/AMPK signaling pathway. Biomed Pharmacother. 2023;165:115164.","journal-title":"Biomed Pharmacother"},{"key":"1892_CR196","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2021.109739","volume":"351","author":"J Zhang","year":"2022","unstructured":"Zhang J, Yang F, Mei X, Yang R, Lu B, Wang Z, et al. Toosendanin and isotoosendanin suppress triple-negative breast cancer growth via inducing necrosis, apoptosis and autophagy. Chem Biol Interact. 2022;351:109739.","journal-title":"Chem Biol Interact"},{"key":"1892_CR197","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.cmet.2018.04.022","volume":"28","author":"W Li","year":"2018","unstructured":"Li W, Tanikawa T, Kryczek I, Xia H, Li G, Wu K, et al. Aerobic glycolysis controls myeloid-derived suppressor cells and tumor immunity via a specific CEBPB isoform in triple-negative breast cancer. Cell Metab. 2018;28:87\u2013103.e6.","journal-title":"Cell Metab"},{"key":"1892_CR198","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1038\/s41420-023-01600-0","volume":"9","author":"X Zhang","year":"2023","unstructured":"Zhang X, Shan G, Li N, Chen J, Ji C, Li X, et al. An autophagy-inducing stapled peptide induces mitochondria dysfunction and triggers autotic cell death in triple-negative breast cancer. Cell Death Discov. 2023;9:303.","journal-title":"Cell Death Discov"},{"key":"1892_CR199","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1038\/s12276-023-00971-9","volume":"55","author":"J Jin","year":"2023","unstructured":"Jin J, Byun JK, Choi YK, Park KG. Targeting glutamine metabolism as a therapeutic strategy for cancer. Exp Mol Med. 2023;55:706\u201315.","journal-title":"Exp Mol Med"},{"key":"1892_CR200","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s40139-017-0139-5","volume":"5","author":"R Kang","year":"2017","unstructured":"Kang R, Tang D. Autophagy and ferroptosis - what\u2019s the connection? Curr Pathobiol Rep. 2017;5:153\u20139.","journal-title":"Curr Pathobiol Rep"},{"key":"1892_CR201","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2025.111869","volume":"134","author":"B Wang","year":"2025","unstructured":"Wang B, Liu ZH, Li JJ, Xu JX, Guo YM, Zhang JX, et al. Role of ferroptosis in breast cancer: molecular mechanisms and therapeutic interventions. Cell Signal. 2025;134:111869.","journal-title":"Cell Signal"},{"key":"1892_CR202","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioadv.2024.213868","volume":"161","author":"NG Shetake","year":"2024","unstructured":"Shetake NG, Das SK, Kumar A, Pandey BN. Nano-inducer of ferroptosis for targeted chemotherapy of human triple-negative breast carcinoma. Biomater Adv. 2024;161:213868.","journal-title":"Biomater Adv"},{"key":"1892_CR203","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.117558","volume":"180","author":"Z Lin","year":"2024","unstructured":"Lin Z, Liu Z, Yang X, Pan Z, Feng Y, Zhang Y, et al. Simeprevir induces ferroptosis through \u03b2-TrCP\/Nrf2\/GPX4 axis in triple-negative breast cancer cells. Biomed Pharmacother. 2024;180:117558.","journal-title":"Biomed Pharmacother"},{"key":"1892_CR204","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.freeradbiomed.2025.04.052","volume":"235","author":"E Zhang","year":"2025","unstructured":"Zhang E, Wang Y, Zhang H, Li X, Su Y, Cui J, et al. Resveratrol induces ferroptosis in triple-negative breast cancer through NEDD4L-mediated GPX4 ubiquitination and degradation. Free Radic Biol Med. 2025;235:231\u201347.","journal-title":"Free Radic Biol Med"},{"key":"1892_CR205","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2025.111760","volume":"131","author":"X Ma","year":"2025","unstructured":"Ma X, Cao D, Zhang Y, Ding X, Hu Z, Wang J. Apatinib combined with paclitaxel suppresses synergistically TNBC progression through enhancing ferroptosis susceptibility regulated SLC7A11\/GPX4\/ACSL4 axis. Cell Signal. 2025;131:111760.","journal-title":"Cell Signal"},{"key":"1892_CR206","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2025.156611","volume":"141","author":"X Wu","year":"2025","unstructured":"Wu X, Jin L, Ren D, Huang S, Meng X, Wu Z, et al. \u03b1-Hederin causes ferroptosis in triple-negative breast cancer through modulating IRF1 to suppress GPX4. Phytomedicine. 2025;141:156611.","journal-title":"Phytomedicine"},{"key":"1892_CR207","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.jare.2024.09.027","volume":"74","author":"G Huang","year":"2025","unstructured":"Huang G, Cai Y, Ren M, Zhang X, Fu Y, Cheng R, et al. Salidroside sensitizes triple-negative breast cancer to ferroptosis by SCD1-mediated lipogenesis and NCOA4-mediated ferritinophagy. J Adv Res. 2025;74:589\u2013607.","journal-title":"J Adv Res"},{"key":"1892_CR208","doi-asserted-by":"publisher","first-page":"131","DOI":"10.2967\/jnumed.122.264152","volume":"64","author":"R Zhou","year":"2023","unstructured":"Zhou R, Choi H, Cao J, Pantel A, Gupta M, Lee HS, et al. 18F-Fluciclovine PET imaging of glutaminase inhibition in breast cancer models. J Nucl Med. 2023;64:131\u20136.","journal-title":"J Nucl Med"},{"key":"1892_CR209","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s12282-023-01502-0","volume":"30","author":"N Vidula","year":"2023","unstructured":"Vidula N, Yau C, Rugo HS. Glutaminase (GLS1) gene expression in primary breast cancer. Breast Cancer. 2023;30:1079\u201384.","journal-title":"Breast Cancer"},{"key":"1892_CR210","doi-asserted-by":"publisher","first-page":"9342","DOI":"10.1074\/jbc.RA119.008180","volume":"294","author":"LMD Reis","year":"2019","unstructured":"Reis LMD, Adamoski D, Ornitz Oliveira Souza R, Rodrigues Ascen\u00e7\u00e3o CF, Sousa de Oliveira KR, Corr\u00eaa-da-Silva F, et al. Dual inhibition of glutaminase and carnitine palmitoyltransferase decreases growth and migration of glutaminase-inhibition-resistant triple-negative breast cancer cells. J Biol Chem. 2019;294:9342\u201357.","journal-title":"J Biol Chem"},{"key":"1892_CR211","doi-asserted-by":"publisher","DOI":"10.1016\/j.mrrev.2021.108366","volume":"787","author":"S Delgir","year":"2021","unstructured":"Delgir S, Bastami M, Ilkhani K, Safi A, Seif F, Alivand MR. The pathways related to glutamine metabolism, glutamine inhibitors and their implication for improving the efficiency of chemotherapy in triple-negative breast cancer. Mutat Res Rev Mutat Res. 2021;787:108366.","journal-title":"Mutat Res Rev Mutat Res"},{"key":"1892_CR212","doi-asserted-by":"publisher","first-page":"e0185092","DOI":"10.1371\/journal.pone.0185092","volume":"12","author":"M Lampa","year":"2017","unstructured":"Lampa M, Arlt H, He T, Ospina B, Reeves J, Zhang B, et al. Glutaminase is essential for the growth of triple-negative breast cancer cells with a deregulated glutamine metabolism pathway and its suppression synergizes with mTOR inhibition. PLoS One. 2017;12:e0185092.","journal-title":"PLoS One"},{"key":"1892_CR213","doi-asserted-by":"publisher","DOI":"10.1016\/j.mtbio.2023.100577","volume":"19","author":"C Yu","year":"2023","unstructured":"Yu C, Wang N, Chen X, Jiang Y, Luan Y, Qin W, et al. A photodynamic-mediated glutamine metabolic intervention nanodrug for triple-negative breast cancer therapy. Mater Today Bio. 2023;19:100577.","journal-title":"Mater Today Bio"},{"key":"1892_CR214","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.112980","volume":"210","author":"WX Zhou","year":"2021","unstructured":"Zhou WX, Chen C, Liu XQ, Li Y, Lin YL, Wu XT, et al. Discovery and optimization of withangulatin A derivatives as novel glutaminase 1 inhibitors for the treatment of triple-negative breast cancer. Eur J Med Chem. 2021;210:112980.","journal-title":"Eur J Med Chem"},{"key":"1892_CR215","doi-asserted-by":"publisher","first-page":"4375","DOI":"10.3390\/molecules29184375","volume":"29","author":"R Luo","year":"2024","unstructured":"Luo R, Zhao H, Deng S, Wu J, Wang H, Guo X, et al. Discovery and optimization of ergosterol peroxide derivatives as novel glutaminase 1 inhibitors for the treatment of triple-negative breast cancer. Molecules. 2024;29:4375.","journal-title":"Molecules"},{"key":"1892_CR216","doi-asserted-by":"publisher","DOI":"10.1172\/JCI140100","volume":"131","author":"DN Edwards","year":"2021","unstructured":"Edwards DN, Ngwa VM, Raybuck AL, Wang S, Hwang Y, Kim LC, et al. Selective glutamine metabolism inhibition in tumor cells improves antitumor T lymphocyte activity in triple-negative breast cancer. J Clin Invest. 2021;131:e140100.","journal-title":"J Clin Invest"},{"key":"1892_CR217","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1158\/1535-7163.MCT-13-0870","volume":"13","author":"MI Gross","year":"2014","unstructured":"Gross MI, Demo SD, Dennison JB, Chen L, Chernov-Rogan T, Goyal B, et al. Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer. Mol Cancer Ther. 2014;13:890\u2013901.","journal-title":"Mol Cancer Ther"},{"key":"1892_CR218","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2025.101136","volume":"61","author":"H Choi","year":"2025","unstructured":"Choi H, Gupta M, Sengupta A, Furth EE, Hensley C, Weljie AM, et al. Disruption of redox balance in glutaminolytic triple-negative breast cancer by inhibition of glutaminase and glutamate export. Neoplasia. 2025;61:101136.","journal-title":"Neoplasia"},{"key":"1892_CR219","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1583","volume":"14","author":"Y Yu","year":"2024","unstructured":"Yu Y, Deng H, Wang W, Xiao S, Zheng R, Lv L, et al. LRPPRC promotes glycolysis by stabilising LDHA mRNA and its knockdown plus glutamine inhibitor induces synthetic lethality via m6A modification in triple-negative breast cancer. Clin Transl Med. 2024;14:e1583.","journal-title":"Clin Transl Med"},{"key":"1892_CR220","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1158\/1535-7163.MCT-22-0401","volume":"22","author":"R Mazahreh","year":"2023","unstructured":"Mazahreh R, Mason ML, Gosink JJ, Olson DJ, Thurman R, Hale C, et al. SGN-CD228A is an investigational CD228-directed antibody-drug conjugate with potent antitumor activity across a wide spectrum of preclinical solid tumor models. Mol Cancer Ther. 2023;22:421\u201334.","journal-title":"Mol Cancer Ther"},{"key":"1892_CR221","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2024.103830","volume":"78","author":"L Sun","year":"2024","unstructured":"Sun L, Jia X, Wang K, Li M. Unveiling the future of breast cancer therapy: Cutting-edge antibody-drug conjugate strategies and clinical outcomes. Breast. 2024;78:103830.","journal-title":"Breast"},{"key":"1892_CR222","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102672","volume":"123","author":"A Dri","year":"2024","unstructured":"Dri A, Arpino G, Bianchini G, Curigliano G, Danesi R, De Laurentiis M, et al. Breaking barriers in triple- negative breast cancer (TNBC) - unleashing the power of antibody-drug conjugates (ADCs). Cancer Treat Rev. 2024;123:102672.","journal-title":"Cancer Treat Rev"},{"key":"1892_CR223","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.breast.2022.10.007","volume":"66","author":"M Shastry","year":"2022","unstructured":"Shastry M, Jacob S, Rugo HS, Hamilton E. Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer. Breast. 2022;66:169\u201377.","journal-title":"Breast"},{"key":"1892_CR224","doi-asserted-by":"publisher","first-page":"108","DOI":"10.2174\/0115680096343056240828190900","volume":"25","author":"G Gupta","year":"2025","unstructured":"Gupta G, Hussain MS, Pant K, Ali H, Thapa R, Bhat AA. Antibody-drug conjugates (ADCs): a novel therapy for triple-negative breast cancer (TNBC). Curr Cancer Drug Targets. 2025;25:108\u201312.","journal-title":"Curr Cancer Drug Targets"},{"key":"1892_CR225","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1038\/bjc.2017.367","volume":"117","author":"AH Staudacher","year":"2017","unstructured":"Staudacher AH, Brown MP. Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required? Br J Cancer. 2017;117:1736\u201342.","journal-title":"Br J Cancer"},{"key":"1892_CR226","doi-asserted-by":"publisher","DOI":"10.1186\/s12884-021-04011-0","volume":"21","author":"N Abdi","year":"2021","unstructured":"Abdi N, Alavi A, Pakbaz F, Darabi H. Vaginal misoprostol versus intracervical Foley catheter for cervical ripening in postdate primigravid women: a randomized clinical trial. BMC Pregnancy Childbirth. 2021;21:533.","journal-title":"BMC Pregnancy Childbirth"},{"key":"1892_CR227","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/j.annonc.2021.03.005","volume":"32","author":"A Bardia","year":"2021","unstructured":"Bardia A, Messersmith WA, Kio EA, Berlin JD, Vahdat L, Masters GA, et al. Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I\/II IMMU-132-01 basket trial. Ann Oncol. 2021;32:746\u201356.","journal-title":"Ann Oncol"},{"key":"1892_CR228","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1080\/14737140.2021.1840984","volume":"21","author":"J Sukumar","year":"2021","unstructured":"Sukumar J, Gast K, Quiroga D, Lustberg M, Williams N. Triple-negative breast cancer: promising prognostic biomarkers currently in development. Expert Rev Anticancer Ther. 2021;21:135\u201348.","journal-title":"Expert Rev Anticancer Ther"},{"key":"1892_CR229","doi-asserted-by":"publisher","first-page":"3674","DOI":"10.7150\/thno.98178","volume":"14","author":"X Liu","year":"2024","unstructured":"Liu X, Ma L, Li J, Sun L, Yang Y, Liu T, et al. Trop2-targeted therapies in solid tumors: advances and future directions. Theranostics. 2024;14:3674\u201392.","journal-title":"Theranostics"},{"key":"1892_CR230","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.202500262","volume":"20","author":"Y Lei","year":"2025","unstructured":"Lei Y, Zheng M, Chen P, Seng Ng C, Peng Loh T, Liu H. Linker design for the antibody-drug conjugates: a comprehensive review. ChemMedChem. 2025;20:e202500262.","journal-title":"ChemMedChem"},{"key":"1892_CR231","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1208\/s12248-019-0390-2","volume":"22","author":"JK Burton","year":"2019","unstructured":"Burton JK, Bottino D, Secomb TW. A systems pharmacology model for drug delivery to solid tumors by antibody-drug conjugates: implications for bystander effects. Aaps J. 2019;22:12.","journal-title":"Aaps J"},{"key":"1892_CR232","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","volume":"384","author":"A Bardia","year":"2021","unstructured":"Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med. 2021;384:1529\u201341.","journal-title":"N Engl J Med"},{"key":"1892_CR233","doi-asserted-by":"publisher","first-page":"2991","DOI":"10.1158\/1535-7163.MCT-13-0896","volume":"13","author":"D Sussman","year":"2014","unstructured":"Sussman D, Smith LM, Anderson ME, Duniho S, Hunter JH, Kostner H, et al. SGN-LIV1A: a novel antibody-drug conjugate targeting LIV-1 for the treatment of metastatic breast cancer. Mol Cancer Ther. 2014;13:2991\u20133000.","journal-title":"Mol Cancer Ther"},{"key":"1892_CR234","doi-asserted-by":"publisher","first-page":"4511","DOI":"10.1158\/1078-0432.CCR-20-3757","volume":"27","author":"ML Maitland","year":"2021","unstructured":"Maitland ML, Sachdev JC, Sharma MR, Moreno V, Boni V, Kummar S, et al. First-in-human study of PF-06647020 (Cofetuzumab Pelidotin), an antibody-drug conjugate targeting protein tyrosine kinase 7, in advanced solid tumors. Clin Cancer Res. 2021;27:4511\u201320.","journal-title":"Clin Cancer Res"},{"key":"1892_CR235","doi-asserted-by":"publisher","first-page":"3848","DOI":"10.1158\/0008-5472.CAN-23-4099","volume":"84","author":"ZZ Zhou","year":"2024","unstructured":"Zhou ZZ, Si Y, Zhang J, Chen K, George A, Kim S, et al. A dual-payload antibody-drug conjugate targeting CD276\/B7-H3 elicits cytotoxicity and immune activation in triple-negative breast cancer. Cancer Res. 2024;84:3848\u201363.","journal-title":"Cancer Res"},{"key":"1892_CR236","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022;387:9\u201320.","journal-title":"N Engl J Med"},{"key":"1892_CR237","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.113503","volume":"42","author":"Y Feng","year":"2023","unstructured":"Feng Y, Lee J, Yang L, Hilton MB, Morris K, Seaman S, et al. Engineering CD276\/B7-H3-targeted antibody-drug conjugates with enhanced cancer-eradicating capability. Cell Rep. 2023;42:113503.","journal-title":"Cell Rep"},{"key":"1892_CR238","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102395","volume":"106","author":"E Nicol\u00f2","year":"2022","unstructured":"Nicol\u00f2 E, Giugliano F, Ascione L, Tarantino P, Corti C, Tolaney SM, et al. Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives. Cancer Treat Rev. 2022;106:102395.","journal-title":"Cancer Treat Rev"},{"key":"1892_CR239","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s10238-025-01655-6","volume":"25","author":"Y Lv","year":"2025","unstructured":"Lv Y, Cui X, Li T, Liu C, Wang A, Wang T, et al. Mechanism of action and future perspectives of ADCs in combination with immune checkpoint inhibitors for solid tumors. Clin Exp Med. 2025;25:139.","journal-title":"Clin Exp Med"},{"key":"1892_CR240","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.3390\/pharmaceutics14081707","volume":"14","author":"S Han","year":"2022","unstructured":"Han S, Lim KS, Blackburn BJ, Yun J, Putnam CW, Bull DA, et al. The potential of topoisomerase inhibitor-based antibody-drug conjugates. Pharmaceutics. 2022;14:1707.","journal-title":"Pharmaceutics"},{"key":"1892_CR241","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1097\/COC.0000000000000919","volume":"45","author":"D Kwapisz","year":"2022","unstructured":"Kwapisz D. Sacituzumab govitecan-hziy in breast cancer. Am J Clin Oncol. 2022;45:279\u201385.","journal-title":"Am J Clin Oncol"},{"key":"1892_CR242","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1080\/14796694.2024.2357534","volume":"20","author":"SM Tolaney","year":"2024","unstructured":"Tolaney SM, DeMichele A, Takano T, Rugo HS, Perou C, Lynce F, et al. OptimICE-RD: sacituzumab govitecan + pembrolizumab vs pembrolizumab (\u00b1 capecitabine) for residual triple-negative breast cancer. Future Oncol. 2024;20:2343\u201355.","journal-title":"Future Oncol"},{"key":"1892_CR243","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1038\/s41586-024-08031-6","volume":"635","author":"AE Schade","year":"2024","unstructured":"Schade AE, Perurena N, Yang Y, Rodriguez CL, Krishnan A, Gardner A, et al. AKT and EZH2 inhibitors kill TNBCs by hijacking mechanisms of involution. Nature. 2024;635:755\u201363.","journal-title":"Nature"},{"key":"1892_CR244","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.semcancer.2020.05.010","volume":"72","author":"KK Wong","year":"2021","unstructured":"Wong KK. DNMT1: a key drug target in triple-negative breast cancer. Semin Cancer Biol. 2021;72:198\u2013213.","journal-title":"Semin Cancer Biol"},{"key":"1892_CR245","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2967\/jnumed.117.192286","volume":"59","author":"KE Henry","year":"2018","unstructured":"Henry KE, Dilling TR, Abdel-Atti D, Edwards KJ, Evans MJ, Lewis JS. Noninvasive 89Zr-transferrin PET shows improved tumor targeting compared with (18)F-FDG PET in MYC-overexpressing human triple-negative breast cancer. J Nucl Med. 2018;59:51\u20137.","journal-title":"J Nucl Med"},{"key":"1892_CR246","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3389\/fendo.2020.00035","volume":"11","author":"AR Michmerhuizen","year":"2020","unstructured":"Michmerhuizen AR, Chandler B, Olsen E, Wilder-Romans K, Moubadder L, Liu M, et al. Seviteronel, a novel CYP17 lyase inhibitor and androgen receptor antagonist, radiosensitizes AR-positive triple-negative breast cancer cells. Front Endocrinol. 2020;11:35.","journal-title":"Front Endocrinol"},{"key":"1892_CR247","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41591-023-02210-0","volume":"29","author":"H Soliman","year":"2023","unstructured":"Soliman H, Hogue D, Han H, Mooney B, Costa R, Lee MC, et al. Oncolytic T-VEC virotherapy plus neoadjuvant chemotherapy in nonmetastatic triple-negative breast cancer: a phase 2 trial. Nat Med. 2023;29:450\u20137.","journal-title":"Nat Med"},{"key":"1892_CR248","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1200\/JCO.2014.57.1414","volume":"33","author":"FJ Couch","year":"2015","unstructured":"Couch FJ, Hart SN, Sharma P, Toland AE, Wang X, Miron P, et al. Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. J Clin Oncol. 2015;33:304\u201311.","journal-title":"J Clin Oncol"},{"key":"1892_CR249","doi-asserted-by":"publisher","first-page":"940","DOI":"10.3390\/pharmaceutics16070940","volume":"16","author":"YR He","year":"2024","unstructured":"He YR, Xia H, Yun P, Xu Y, Ma WMJ, Xiao ZX, et al. \u03b1-Lactalbumin mRNA-LNP evokes an anti-tumor effect combined with surgery in triple-negative breast cancer. Pharmaceutics. 2024;16:940.","journal-title":"Pharmaceutics"},{"key":"1892_CR250","doi-asserted-by":"publisher","first-page":"TPS1125","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS1125","volume":"40","author":"GT Budd","year":"2022","unstructured":"Budd GT, Johnson JM, Rhoades EE, Moore HCF, Kruse ML, Roesch EE, et al. Phase I trial of an alpha-lactalbumin vaccine in patients with moderate- to high-risk operable triple-negative breast cancer (TNBC). J Clin Oncol. 2022;40:TPS1125.","journal-title":"J Clin Oncol"},{"key":"1892_CR251","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01805-y","volume":"22","author":"F Ye","year":"2023","unstructured":"Ye F, Dewanjee S, Li Y, Jha NK, Chen ZS, Kumar A, et al. Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer. Mol Cancer. 2023;22:105.","journal-title":"Mol Cancer"},{"key":"1892_CR252","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1093\/annonc\/mdz395","volume":"30","author":"JH Park","year":"2019","unstructured":"Park JH, Jonas SF, Bataillon G, Criscitiello C, Salgado R, Loi S, et al. Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy. Ann Oncol. 2019;30:1941\u20139.","journal-title":"Ann Oncol"},{"key":"1892_CR253","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1001\/jama.2024.3056","volume":"331","author":"RA Leon-Ferre","year":"2024","unstructured":"Leon-Ferre RA, Jonas SF, Salgado R, Loi S, de Jong V, Carter JM, et al. Tumor-infiltrating lymphocytes in triple-negative breast cancer. Jama. 2024;331:1135\u201344.","journal-title":"Jama"},{"key":"1892_CR254","doi-asserted-by":"publisher","first-page":"TPS79","DOI":"10.1200\/JCO.2018.36.5_suppl.TPS79","volume":"36","author":"JM Specht","year":"2018","unstructured":"Specht JM, Lee S, Turtle C, Berger C, Veatch J, Gooley T, et al. Phase I study of immunotherapy for advanced ROR1+ malignancies with autologous ROR1-specific chimeric antigen receptor-modified (CAR)-T cells. J Clin Oncol. 2018;36:TPS79.","journal-title":"J Clin Oncol"},{"key":"1892_CR255","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1385571","volume":"15","author":"Z Niu","year":"2024","unstructured":"Niu Z, Wu J, Zhao Q, Zhang J, Zhang P, Yang Y. CAR-based immunotherapy for breast cancer: peculiarities, ongoing investigations, and future strategies. Front Immunol. 2024;15:1385571.","journal-title":"Front Immunol"},{"key":"1892_CR256","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ccell.2018.11.016","volume":"35","author":"M Shen","year":"2019","unstructured":"Shen M, Jiang YZ, Wei Y, Ell B, Sheng X, Esposito M, et al. Tinagl1 suppresses triple-negative breast cancer progression and metastasis by simultaneously inhibiting integrin\/FAK and EGFR signaling. Cancer Cell. 2019;35:64\u201380.e7.","journal-title":"Cancer Cell"},{"key":"1892_CR257","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1200\/JCO.19.01304","volume":"38","author":"JK Litton","year":"2020","unstructured":"Litton JK, Scoggins ME, Hess KR, Adrada BE, Murthy RK, Damodaran S, et al. Neoadjuvant talazoparib for patients with operable breast cancer with a germline BRCA pathogenic variant. J Clin Oncol. 2020;38:388\u201394.","journal-title":"J Clin Oncol"},{"key":"1892_CR258","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1158\/1078-0432.CCR-21-2080","volume":"28","author":"JL Blum","year":"2022","unstructured":"Blum JL, Laird AD, Litton JK, Rugo HS, Ettl J, Hurvitz SA, et al. Determinants of response to talazoparib in patients with HER2-negative, germline BRCA1\/2-mutated breast cancer. Clin Cancer Res. 2022;28:1383\u201390.","journal-title":"Clin Cancer Res"},{"key":"1892_CR259","doi-asserted-by":"publisher","first-page":"5482","DOI":"10.1158\/1078-0432.CCR-21-0310","volume":"27","author":"NC Turner","year":"2021","unstructured":"Turner NC, Balma\u00f1a J, Poncet C, Goulioti T, Tryfonidis K, Honkoop AH, et al. Niraparib for advanced breast cancer with germline BRCA1 and BRCA2 mutations: the EORTC 1307-BCG\/BIG5-13\/TESARO PR-30-50-10-C BRAVO study. Clin Cancer Res. 2021;27:5482\u201391.","journal-title":"Clin Cancer Res"},{"key":"1892_CR260","doi-asserted-by":"publisher","DOI":"10.1200\/PO-25-00090","volume":"9","author":"S Anbil","year":"2025","unstructured":"Anbil S, Seewald NJ, Chiorean EG, Hussein M, Kasi PM, Laux DE, et al. LODESTAR: a single-arm phase ii study of rucaparib in solid tumors with pathogenic germline or somatic variants in homologous recombination repair genes. JCO Precis Oncol. 2025;9:e2500090.","journal-title":"JCO Precis Oncol"},{"key":"1892_CR261","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s10549-021-06292-7","volume":"189","author":"J Xu","year":"2021","unstructured":"Xu J, Keenan TE, Overmoyer B, Tung NM, Gelman RS, Habin K, et al. Phase II trial of veliparib and temozolomide in metastatic breast cancer patients with and without BRCA1\/2 mutations. Breast Cancer Res Treat. 2021;189:641\u201351.","journal-title":"Breast Cancer Res Treat"},{"key":"1892_CR262","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1002\/cncr.35270","volume":"130","author":"J Wu","year":"2024","unstructured":"Wu J, Wang W, Gao L, Shao X, Wang X. Cyclin-dependent kinase inhibitors enhance programmed cell death protein 1 immune checkpoint blockade efficacy in triple-negative breast cancer by affecting the immune microenvironment. Cancer. 2024;130:1449\u201363.","journal-title":"Cancer"},{"key":"1892_CR263","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.cell.2015.08.063","volume":"163","author":"Y Wang","year":"2015","unstructured":"Wang Y, Zhang T, Kwiatkowski N, Abraham BJ, Lee TI, Xie S, et al. CDK7-dependent transcriptional addiction in triple-negative breast cancer. Cell. 2015;163:174\u201386.","journal-title":"Cell"},{"key":"1892_CR264","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.clbc.2013.10.016","volume":"14","author":"MM Mita","year":"2014","unstructured":"Mita MM, Joy AA, Mita A, Sankhala K, Jou YM, Zhang D, et al. Randomized phase II trial of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus capecitabine in patients with advanced breast cancer. Clin Breast Cancer. 2014;14:169\u201376.","journal-title":"Clin Breast Cancer"},{"key":"1892_CR265","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202318459","volume":"15","author":"L Pascual-Reguant","year":"2023","unstructured":"Pascual-Reguant L, Serra-Camprub\u00ed Q, Datta D, Cianferoni D, Kourtis S, Ga\u00f1ez-Zapater A, et al. Interactions between BRD4S, LOXL2, and MED1 drive cell cycle transcription in triple-negative breast cancer. EMBO Mol Med. 2023;15:e18459.","journal-title":"EMBO Mol Med"},{"key":"1892_CR266","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-020-01354-y","volume":"22","author":"AC Garrido-Castro","year":"2020","unstructured":"Garrido-Castro AC, Saura C, Barroso-Sousa R, Guo H, Ciruelos E, Bermejo B, et al. Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer. Breast Cancer Res. 2020;22:120.","journal-title":"Breast Cancer Res"},{"key":"1892_CR267","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-018-1015-x","volume":"20","author":"P Sch\u00f6ffski","year":"2018","unstructured":"Sch\u00f6ffski P, Cresta S, Mayer IA, Wildiers H, Damian S, Gendreau S, et al. A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer. Breast Cancer Res. 2018;20:109.","journal-title":"Breast Cancer Res"},{"key":"1892_CR268","doi-asserted-by":"publisher","DOI":"10.1186\/bcr3605","volume":"16","author":"D Zardavas","year":"2014","unstructured":"Zardavas D, Phillips WA, Loi S. PIK3CA mutations in breast cancer: reconciling findings from preclinical and clinical data. Breast Cancer Res. 2014;16:201.","journal-title":"Breast Cancer Res"},{"key":"1892_CR269","doi-asserted-by":"publisher","first-page":"10208","DOI":"10.1073\/pnas.0907011107","volume":"107","author":"S Loi","year":"2010","unstructured":"Loi S, Haibe-Kains B, Majjaj S, Lallemand F, Durbecq V, Larsimont D, et al. PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Proc Natl Acad Sci USA. 2010;107:10208\u201313.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1892_CR270","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1093\/annonc\/mdz177","volume":"30","author":"M Oliveira","year":"2019","unstructured":"Oliveira M, Saura C, Nuciforo P, Calvo I, Andersen J, Passos-Coelho JL, et al. FAIRLANE, a double-blind, placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer. Ann Oncol. 2019;30:1289\u201397.","journal-title":"Ann Oncol"},{"key":"1892_CR271","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s10549-021-06450-x","volume":"191","author":"N Turner","year":"2022","unstructured":"Turner N, Dent RA, O\u2019Shaughnessy J, Kim SB, Isakoff SJ, Barrios C, et al. Ipatasertib plus paclitaxel for PIK3CA\/AKT1\/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial. Breast Cancer Res Treat. 2022;191:565\u201376.","journal-title":"Breast Cancer Res Treat"},{"key":"1892_CR272","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1016\/j.drudis.2019.09.001","volume":"24","author":"MA Khan","year":"2019","unstructured":"Khan MA, Jain VK, Rizwanullah M, Ahmad J, Jain K. PI3K\/AKT\/mTOR pathway inhibitors in triple-negative breast cancer: a review on drug discovery and future challenges. Drug Discov Today. 2019;24:2181\u201391.","journal-title":"Drug Discov Today"},{"key":"1892_CR273","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s10549-025-07747-x","volume":"212","author":"S Phadke","year":"2025","unstructured":"Phadke S, Miller KD, Shah A, Danciu OC, Chen Y, Yu M, et al. Phase I\/II trial investigating gedatolisib plus talazoparib in advanced triple-negative or BRCA1\/2 positive, HER2-negative breast cancers. Breast Cancer Res Treat. 2025;212:521\u201330.","journal-title":"Breast Cancer Res Treat"},{"key":"1892_CR274","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s40268-024-00459-5","volume":"24","author":"A Moein","year":"2024","unstructured":"Moein A, Jin JY, Wright MR, Alicke B, Wong H. Retrospective assessment of translational pharmacokinetic-pharmacodynamic modeling performance: a case study with apitolisib, a dual PI3K\/mTOR inhibitor. Drugs R D. 2024;24:155\u201367.","journal-title":"Drugs R D"},{"key":"1892_CR275","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1245\/s10434-013-3260-7","volume":"21","author":"LJ McGhan","year":"2014","unstructured":"McGhan LJ, McCullough AE, Protheroe CA, Dueck AC, Lee JJ, Nunez-Nateras R, et al. Androgen receptor-positive triple-negative breast cancer: a unique breast cancer subtype. Ann Surg Oncol. 2014;21:361\u20137.","journal-title":"Ann Surg Oncol"},{"key":"1892_CR276","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.3892\/ol.2013.1602","volume":"6","author":"J Tuomela","year":"2013","unstructured":"Tuomela J, Sandholm J, Kauppila JH, Lehenkari P, Harris KW, Selander KS. Chloroquine has tumor-inhibitory and tumor-promoting effects in triple-negative breast cancer. Oncol Lett. 2013;6:1665\u201372.","journal-title":"Oncol Lett"},{"key":"1892_CR277","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.12518","volume":"51","author":"C Cao","year":"2018","unstructured":"Cao C, Huang W, Zhang N, Wu F, Xu T, Pan X, et al. Narciclasine induces autophagy-dependent apoptosis in triple-negative breast cancer cells by regulating the AMPK-ULK1 axis. Cell Prolif. 2018;51:e12518.","journal-title":"Cell Prolif"},{"key":"1892_CR278","doi-asserted-by":"publisher","first-page":"e0177694","DOI":"10.1371\/journal.pone.0177694","volume":"12","author":"Z Liu","year":"2017","unstructured":"Liu Z, He K, Ma Q, Yu Q, Liu C, Ndege I, et al. Autophagy inhibitor facilitates gefitinib sensitivity in vitro and in vivo by activating mitochondrial apoptosis in triple-negative breast cancer. PLoS One. 2017;12:e0177694.","journal-title":"PLoS One"},{"key":"1892_CR279","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.annonc.2023.11.018","volume":"35","author":"LM Spring","year":"2024","unstructured":"Spring LM, Tolaney SM, Fell G, Bossuyt V, Abelman RO, Wu B, et al. Response-guided neoadjuvant sacituzumab govitecan for localized triple-negative breast cancer: results from the NeoSTAR trial. Ann Oncol. 2024;35:293\u2013301.","journal-title":"Ann Oncol"},{"key":"1892_CR280","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.638482","volume":"11","author":"T Pascual","year":"2021","unstructured":"Pascual T, Oliveira M, Ciruelos E, Bellet Ezquerra M, Saura C, Gavil\u00e1 J, et al. SOLTI-1805 TOT-HER3 study concept: a window-of-opportunity trial of patritumab deruxtecan, a HER3-directed antibody-drug conjugate, in patients with early breast cancer. Front Oncol. 2021;11:638482.","journal-title":"Front Oncol"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01892-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01892-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01892-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T09:02:48Z","timestamp":1789635768000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01892-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,4]]},"references-count":280,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1892"],"URL":"https:\/\/doi.org\/10.1038\/s41401-026-01892-9","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,4]]},"assertion":[{"value":"25 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}